acnp summer council meeting agenda 8:30 a.m. 3:30 p.m. est...

ACNP Summer Council Meeting Agenda

Sunday, June 23, 2013

8:30 a.m. – 3:30 p.m. EST

Room 303, Westin Diplomat

David Lewis, Presiding

*Nominating Committee 2013 – Please complete the ballot and give your completed ballot to

Laura or Sarah before you leave the meeting on June 23rd. (pages 1-2)

*Hoch Award – Bill Carlezon has nominated Dr. Jim Meador-Woodruff for his service to the

journal for the award. Award specifications and nomination are also behind page 3-5.

1. 8:30 a.m. – Program Committee Report – Randy Blakely to join.

2. 9:00 a.m. - Treasurer’s Report –

a. FY2012 Audit Report (pages 6-27)

b. Investment Report

i. SunTrust (pages 28-53)

ii. Olympia Neu (pages 54-64)

3. 9:15 a.m. - Associate Member Termination – Richard Bergeron was elected to associate

membership in 2009 and missed 3 meetings (2010-2012). An attendance reminder letter

(page 65) was sent from the Executive Office on Dr. Frazer’s behalf in March of 2012 with

no response received. In a March 26, 2013 letter (page 66) Dr. Bergeron’s associate

membership was terminated per the ACNP By-laws. The Executive Office received the

attached request (page 67) for continued membership from Dr. Bergeron.

4. 9:30 a.m. – Room Block for ACNP Annual Meeting at the Westin Diplomat – Ronnie

Wilkins to update.

5. 9:45 a.m. - Meeting Locations for 2018 & 2019 – In December, Council decided to continue

meeting at the Westin Diplomat for 2018 and 2019. Since we have been here in 2012 and

again in 2013, and have contracts completed for 2015 and 2016. Do you want to consider an

alternative venue for either 2018 or 2019?

6. 10:00 a.m. - Childcare at the Annual Meeting – Do we want to continue offering childcare at

the Annual Meeting? Last year, we had 15 children from 10 families use the service.

7. 10:15 a.m. – Nasrallah Gift – In late December, 2012 Dr. Henry Nasrallah and his wife gave

1,000 shares of Phillips 66 stock to the ACNP. At the time of donation the stock was valued at

$50,570. We have attached correspondence related to this gift (pages 68-75). The action for us

this year is to announce during the awards ceremony at the beginning of the President’s Plenary

session that we will have a new award beginning in 2014. The award will be either the Young

Investigator Research Award for Serious and Persistent Mental Illness, or the Young

Investigator Award for Psychosis Research. We need to decide which name.

8. Career Development Institute for Psychiatry Trainee Class – Request to meet at the ACNP

Annual Meeting. (page 76)

9. 10:30 a.m. – Discussion on National Mental Health Conference at the White House. See

pages 77-83.

10. 10:45 a.m. - Committee & Task Force Reports – (pages 84-90)

11. 11:00 a.m. - Strategic Plan Discussion/Updates – (pages 91-101)

ACNP FELLOWS ELIGIBLE FOR ELECTION TO THE 2013 NOMINATING COMMITTEE

Please circle ten (10) to fifteen (15) names for the 2013 Nominating Committee

FELLOWS Abel, Ted Abercrombie,

Elizabeth Adinoff, Bryon Alexopoulos, George Andreasen, Nancy Anthony, James Anton, Raymond Arango, Victoria Artigas, Francesc Asberg, Marie Aston-Jones, Gary Balster, Robert Barchas, Jack Barondes, Samuel Barrett, James Bartus, Raymond Baxter, Lewis Beasley, Charles Beck, Sheryl Bellack, Alan Benes, Francine Berrettini, Wade Bethea, Cynthia Biggio, Giovanni Bissette, Garth Blakely, Randy Blier, Pierre Bowden, Charles Breese, George Branchek, Theresa Brody, Arthur Brown, Alan Brown, Lawrence Buchanan, Robert Bunney, William Buxbaum, Joseph Cadenhead, Kristin Calabrese, Joseph Carlezon, William Carlsson, Arvid Carroll, Marilyn Carter, Cameron Casey, Daniel Charney, Dennis Chase, Thomas Chuang, De-Maw Chavkin, Charles Cicero, Theodore Civelli, Olivier Coccaro, Emil Cohen, Bruce Conley, Robert Coyle, Joseph Crews, Fulton Cunningham, Kathryn Davidson, Michael

Davis, John Davis, Kenneth De Souza, Errol de Wit, Harriet Deakin, John (Bill) DeLisi, Lynn Deutch, Ariel Deutsch, Stephen DeVane, C. Lindsay Drevets, Wayne Dubocovich, Margarita Ebert, Michael Ehlers, Cindy Emslie, Graham Endicott, Jean Enna, Salvatore Ernst, Monique Escobar, Javier Essock, Susan Evans, Dwight Everitt, Barry Fatemi, S. Hossein Fawcett, Jan Fieve, Ronald Fleischhacker, Wolfgang Foltin, Richard Frank, Ellen Freed, William Gelenberg, Alan George, Mark George, Tony Gershon, Elliot Geyer, Mark Giedd, Jay Gilmore, John Gjedde, Albert Gogtay, Nitin Goldberg, Terry Golden, Robert Goldman, David Goodwin, Frederick Goodwin, Guy Grace, Anthony Grandy, David Greden, John Green, Alan Green, Michael Greene, Robert Greengard, Paul Griffiths, Roland Gur, Ruben Halaris, Angelos Halbreich, Uriel Haroutunian, Vahram Harris, James Harvey, Philip Heckers, Stephan

Heilig, Markus Higley, J. Dee Hill, Shirley Hirschfeld, Robert Hollander, Eric Holsboer, Florian Hyman, Steven Innis, Robert Insel, Thomas Iyengar, Smriti Javitt, Daniel Jeste, Dilip Jimerson, David Johnson, Bankole Jones, Edward Judd, Lewis Kalin, Ned Kandel, Eric Kane, John Kaye, Walter Keefe, Richard Keller, Martin Kelsoe, John Kilts, Clinton Kleber, Herbert Kleinman, Joel Koob, George Koslow, Stephen Kosten, Thomas Kranzler, Henry Kreek, Mary Jeanne Krishnan, Ranga Kuhn, Cynthia Kumar, Anand Leckman, James Lerer, Bernard Liberzon, Israel Licinio, Julio Lieberman, Jeffrey Lipska, Barbara Loh, Horace London, Edythe Lucki, Irwin Lyketsos, Constantine Mailman, Richard Malaspina, Dolores Manji, Husseini Marder, Stephen Markou, Athina Mason, Barbara Mathe, Aleksander McCarley, Robert McDougle, Christopher Meador-Woodruff, James Mello, Nancy Meltzer, Carolyn Meltzer, Herbert Merikangas, Kathleen

Merlo-Pich, Emilio Meyer, Roger Meyer-Lindenberg,

Andreas Miller, Andrew Mirnics, Karoly Mohler, Hanns Mohs, Richard Morilak, David Mueller, Walter Murphy, Dennis Nasrallah, Henry Nemeroff, Charles Nurnberger, John Neumaier, John Neumeister, Alexander Nixon, Ralph Nopoulos, Peg Nurnberger, John O’Donnell, James O’Donnell, Patricio Ogren, Sven Ove Oquendo, Maria Owens, Michael Palfreyman, Michael Pandey, Ghanshyam Paul, Steven Pearlson, Godfrey Peskind, Elaine Pfefferbaum, Adolf Phillips, Katharine Phillips, Mary Pickar, David Pollack, Mark Post, Robert Price, Lawrence Racagni, Giorgio Rapaport, Mark Rapoport, Judith Rapoport, Stanley Rasenick, Mark Rasgon, Natalie Raskind, Murray Rauch, Scott Reisberg, Barry Ressler, Kerry Richelson, Elliott Robinson, Robert Role, Lorna Roques, Bernard Rosenbaum, Jerrold Roth, Bryan Rothschild, Anthony Roy-Byrne, Peter Rubinow, David Rush, A., John Sackeim, Harold Salzman, Carl

ACNP FELLOWS ELIGIBLE FOR ELECTION TO THE 2013 NOMINATING COMMITTEE

Please circle ten (10) to fifteen (15) names for the 2013 Nominating Committee

FELLOWS CON’T Sanacora, Gerard Sanberg, Paul Sanders-Bush, Elaine Sawa, Akira Schatzberg, Alan Schlaepfer, Thomas Schmidt, Peter Schneider, Lon Schooler, Nina Schuckit, Marc Schwarcz, Robert See, Ronald Self, David Sellers, Edward Sesack, Susan Shalev, Arieh Shekhar, Anantha Sheline, Yvette Shenton, Martha Shih, Jean Sibley, David Siegel, Steven Siever, Larry Skolnick, Phil Small, Gary Smith, Gwenn Smith, Robert Snyder, Solomon Spiegel, David Stahl, Stephen Stein, Elliot Stein, Murray Strakowski, Stephen Sunderland, Trey Suppes, Trisha Svensson, Torgny Swann, Alan Swedo, Susan Sweet, Robert Swerdlow, Neal Swift, Robert Tabakoff, Boris Tarazi, Frank Tohen, Mauricio Uhde, Thomas Valentino, Rita Vezina, Paul Volkow, Nora Waddington, John Wagner, Karen Watson, Stanley Weinberger, Daniel Weiss, Friedbert Weiss, Jay Weissman, Myrna Williams, Janet Wisner, Katherine

Wong, Dean Wong, Dona Lee Woods, James Yamawaki, Shigeto Yehuda, Rachel Young, Alice Young, Robert Youdim, Moussa Zohar, Joseph Zubenko, George Zubieta, Jon-Kar Zukin, R., Suzanne

FELLOWS EMERITUS Adler, Martin Aghajanian, George Agranoff, Bernard Alpert, Murray Angrist, Burt Angst, Jules Appel, James Azmitia, Efrain Baldessarini, Ross Ballenger, James Ban, Thomas Belmaker, Robert Blackwell, Barry Bloom, Floyd Borbely, Alexander Breese, George Breitner, John Brown, Walter Bunney, Benjamin Callaway, Enoch Campbell, Magda Carpenter, William Carroll, Bernard Clayton, Paula Conners, C. Keith Cook, Leonard Coppen, Alec Crow, Timothy Davidson, Jonathan Davis, Michael DeVeaugh-Geiss, Joseph Dingell, James Domino, Edward Dunner, David Eichelman, Burr Elkes, Joel Fann, W. Edwin Fibiger, H. Christian Fink, Max Fish, Barbara Fisher, Seymour Fuxe, Kjell

Gabay, Sabit Gallant, Don Garattini, Silvio Garver, David Gershon, Samuel Glick, Ira Goldstein, Burton Groves, Philip Halmi, Katherine Hanin, Israel Hanlon, Thomas Hargreaves, William Harris, Louis Hartmann, Ernest Hellhammer, Dirk Heninger, George Henn, Fritz Hippius, Hanns Hoffmeister, Friedrich Holaday, John Hornykiewicz, Oleh Itil, Turan Iversen, Leslie Jacobowitz, David Jaffe, Jerome Janowsky, David Jenden, Donald Jones, Reese Karczmar, Alexander Katz, Martin Klee, Gerald Klein, Donald Klein, Rachel Klett, James Kocsis, James Kopin, Irwin Kornetsky, Conan Kuhar, Michael Kuntzman, Ronald Lake, C., Raymond Landau, Emmanuel Langer, Salomon Lemberger, Louis Lenox, Robert Leonard, Brian Levine, Jerome Lewy, Alfred Li, Ting-Kai Lipman, Ronald Lloyd, G., Kenneth Lovenberg, Walter Malitz, Sidney Mandell, Arnold Mann, J., John McKinney, William Mendels, Joseph Mendlewicz, Julien Mirsky, Allan Molinoff, Perry

Moore, Kenneth Neff, Norton Noble, Ernest O'Brien, Charles Overall, John Oxenkrug, Gregory Pardes, Herbert Pauls, David Paykel, Eugene Pichot, Pierre Pitman, Roger Potter, William Prange, Arthur Raskin, Allen Rech, Richard Redmond, D. Eugene Resnick, Richard Reynolds, Charles Rickels, Karl Rifkin, Arthur Robinson, Donald Rose, Robert Rubin, Robert Salmoiraghi, Gian Sandler, Merton Satterfield, James Schneider, Jurg Schuckit, Marc Sedvall, Goran Shader, Richard, Simpson, George Sokoloff, Louis Sourkes, Theodore Spitzer, Robert Stein, Larry Sulser, Fridolin Szara, Stephen Tecce, Joseph Tedeschi, David Tinklenberg, Jared Tsuang, Ming Uhlenhuth, E. H. van Kammen, Daniel van Praag, Herman Vinar, Oldrich Way, E. Leong Wender, Paul Wetterberg, Lennart Wurtman, Richard Yanagita, Tomoji

2013 ACNP Paul Hoch Distinguished Service Award 1. The Paul Hoch Distinguished Service Award is presented by the ACNP when a

member has made unusually significant contributions to the College. The emphasis

of this award is on service to the College—not for teaching, clinical, or research

accomplishment. Recipients of the Hoch Award will receive a monetary award and a

plaque to be given at the Annual Meeting in Hollywood, Florida, December 8-12,

2013.

2. Any Member or Fellow of the ACNP may submit the name of a member to receive

the Hoch Award. All submissions shall be made to the Executive Office and include

a description of the candidate’s contributions to the College and a statement about the

significance of his/her contributions. Nomination of women and minorities is highly

encouraged.

3. Individuals who have received the Paul Hoch Distinguished Service Award are:

1965 Jonathan O. Cole 1995 Arthur J. Prange, Jr.

1968 Richard Wittenborn 1996 Arnold J. Friedhoff

1973 Theodore Rothman 1998 Floyd E. Bloom

1974 Burtrum C. Schiele 1998 David J Kupfer

1978 Albert DiMascio 1999 Roger E. Meyer

1980 Leo E. Hollister 2000 Herbert Y. Meltzer

1982 Daniel X. Freedman 2002 Eva King Killam

1983 Oakley Ray 2003 Thomas A. Ban

1986 David M. Engelhardt 2004 Irwin J. Kopin

1986 Morris A. Lipton 2005 Ira D. Glick

1988 Frank J. Ayd, Jr. 2007 Kenneth L. Davis

1989 Leonard Cook 2008 William T. Carpenter, Jr.

1990 Keith F. Killiam, Jr. 2009 Charles P. O’Brien

1991 Donald F. Klein 2010 Huda Akil

1993 J. Christian Gillin 2011 Carol A. Tamminga

2012 David L. Braff

Nominations must be submitted on-line: http://www.acnp.org/programs/awards.aspx

http://www.acnp.org/programs/awards.aspx

Mailman Research Center, Room 217, 115 Mill Street, Belmont, Massachusetts, 02478 Telephone: (617) 855-2021, FAX: (617) 855-2023, E-mail: [email protected]

URL: http://www.mclean.harvard.edu/research/mrc/bgl.php

To: ACNP Council Re: Hoch Award nomination

June 14, 2013 Dear Members of ACNP Council: I nominate Dr. James Meador-Woodruff for the 2013 Paul Hoch Distinguished Service Award. Jim made unusually significant contributions to the College over a 6+ year period as Editor-in-Chief of Neuropsychopharmacology. He is an ideal candidate for this prestigious award. Jim took over Neuropsychopharmacology in 2006, during a time of crisis for the journal. As was justified by the circumstances, he brought in an entirely new team of editors and re-established stability and transparency. Despite these challenges, under his leadership the journal has become one of the top journals in our field. He grew the impact factor from 3.80 in 2006 to 7.991—currently the high point in journal history and #6 among all psychiatry journals—in 2011. (The 2012 impact factor is not yet available.) As one of his associate editors for 6 years, I can attest to the fact that he had extraordinary attention to detail and treated everyone involved in the process (authors, reviewers, editors) with a combination of respect and dignity. His decisiveness, fairness, and broad knowledge of the field made him an ideal Editor-in-Chief. I am very proud to have been part of the journal renaissance that he engineered. I will be forever grateful to Jim for getting me interested and excited about the journal and giving me the confidence to apply for the role of Editor-in-Chief when it became open at the end of his 6-year term. Jim handed me the reins of a journal that is clearly on the rise, with improvements in numerous key metrics under his leadership. He has been gracious in every respect, sharing with me the smallest details of how to run a successful journal in a highly competitive field while leaving time and energy for my other job (running an externally funded basic research program). The fact that Jim shared so much of his time and insight during the transition made it possible to rapidly implement some significant changes in the first issue of 2013, without having to dedicate time and effort re-inventing the task of running the journal. In this way the transition was seamless, with no hurdles to slow down our progress or disrupt our trajectory. Although my nomination focuses on Jim’s role as Editor-in-Chief, it may be relevant to point out some other accomplishments that illustrate his innovating thinking on behalf of the college. Jim was also the ACNP’s first website editor. He led the effort to put the 4th and 5th Generations of Progress on the website, making them available free of charge. Under his leadership the ACNP began posting the final accepted draft of papers to be published in the journal on our website within a couple of days of acceptance, essentially the same as our publisher (Nature Publishing Group [NPG]) does for us now, over 10 years ago. While we stopped this process when NPG’s system became efficient enough that there was little advantage to have the draft paper available, the point is that Jim’s vision was prophetic. The website has certainly been

McLean Hospital

Behavioral Genetics Laboratory

Harvard Medical School

Department of Psychiatry

Meador-Woodruff, 2

developed much further under Dave Sibley’s leadership, but Jim did an outstanding job getting it off the ground at a time when there were many technical challenges and demands. All of Jim’s actions as Editor-in-Chief were designed to strengthen the journal, to support his colleagues who would be staying on, and to bring pride to the ACNP. I suspect that Jim might say that someone else deserves this award more than he does, which is precisely why he deserves it so richly. Thank you in advance for your careful consideration of this nomination. Sincerely yours,

William A. Carlezon Jr., Ph.D. Professor of Psychiatry and Neuroscience Editor-in-Chief, Neuropsychopharmacology ACNP Fellow

SunTrust Investment Services, Inc.P O Box 596Richmond, VA 23286-0388

AMERICAN COLLEGE OFNEUROPSYCHOPHARMACOLOGY5034 THOROUGHBRED LN STE ABRENTWOOD TN 37027

Lechelle Moore(800) 874 4770

John Blanchard(615) 748 4905

1 866 855 0090

www.suntrust.com

Bulletin board ....................................... 2

Your SunTrustaccounts summary ............................... 3

Yourcash summary ...................................... 6

Yourinvestments ........................................... 9

Important information .......................... 25

1 of 25

1000050829844

T1F141631

is a service of SunTrust Investment Services, Inc. and SunTrust Bank, which are affiliates of SunTrust Banks,

Inc. Broker dealer services are offered through SunTrust Investment Services, Inc., a member of the Financial Industry Regulatory

Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Registered Representatives are registered representatives

of SunTrust Investment Services, Inc. Banking services are offered through SunTrust Bank, a member of the Federal Deposit

Insurance Corporation (FDIC). SunTrust is a federally registered service mark of SunTrust Banks, Inc.

There are no Action alert messages for youraccount this month.

Unless otherwise specified in writing,securities, investment and insuranceproducts offered through SunTrustInvestment Services, Inc.: - are not FDIC insured - are not bank guaranteed - may lose value.

Signature Advantage

Your Registered Representative

Your Relationship Banker

Priority client services

Website

Your checking account

Your investment account

Signature Advantage

Signature Advantage

Contact information

In this statement

Your monthlystatement for May, 2013

Signature Advantage

000000

2 of 25

AMERICAN COLLEGE OF 1000050829844NEUROPSYCHOPHARMACOLOGY

T1F141631

Customer Your checking account

Your investment account Signature AdvantageSignature Advantage

Signature Advantage

How can we help you make the right financialchoices for today and tomorrow? With our varietyof solutions and financial guidance. We value youas a client and want to help you bank the way thatfits your life.

Learn more at suntrust.com

Signature Advantage clients are provided anexclusive Priority Client Service telephone number,giving you direct access to a customer carerepresentative. Our highly trained and professionalrepresentatives can answer all of your questionsrelated to Signature Advantage, helping you realizethe full benefit associated with SunTrust's premierefinancial management service. Do not hesitate totake advantage of this exclusive service today. Thetoll-free number is located on the first page of thisstatement.

SunTrust will never send emails asking you toprovide, update or verify your personal or accountinformation, such as passwords, social securitynumbers, PINs, credit or check card numbers, orother confidential information.

Learn more at suntrust.com/alert.

Financial Well Being Priority Client Service Help Protect Yourself Against Online Fraud

Your monthly statement for May, 2013 You are hereSignature Advantage

Bulletin board

Your SunTrust accounts summary

Your cash summary

Your investments

Balancing your account

Bulletin Board

3 of 25

* Your is provided for your information and includes accounts held at different financial institutions.

Information about your checking account and any trust or other deposit accounts is provided by SunTrust Bank,

which holds these accounts. Information about your brokerage account and other investment services or margin

accounts is provided by National Financial Services LLC ("NFS") member SIPC and NYSE, which carries these accounts and is the clearing

broker for SunTrust Investment Services, Inc. (member SIPC). SunTrust Bank and SunTrust Mortgage, Inc. provide information on your

loan accounts.

** include the investment sweep, which consists of either one of

the money market mutual funds held at NFS or a SunTrust Bank FDIC insured interest-bearing deposit account, as selected by you, plus

any money market funds held as an investment in your account, uninvested cash and margin account balances. For more information, see

the sections below Your Signature Advantage cash summary - Sweep activity and Your Signature Advantage investments.

cash andcash equivalents 3.5%

investments 96.5%


T1F141631

Value at Value atbeginning of end of Difference

month ($) month ($) this month ($)



SunTrust accounts summary

Signature Advantage

Signature Advantage

"Signature Advantage cash and cash equivalents" Signature Advantage

Signature Advantage

Signature Advantage

Signature AdvantageSignature Advantage

Signature Advantage

cash andcash equivalents** 38,812.72 100,620.43 61,807.71

investments 2,853,968.42 2,794,961.76 (59,006.66 )

Total $2,892,781.14 $2,895,582.19 $2,801.05

Your total SunTrust assets $2,892,781.14 $2,895,582.19 $2,801.05

Your SunTrust assets

Change in the value of yourSunTrust assets


Your account

Your SunTrust assets

Your SunTrust accounts summary*

Signature Advantage

Signature Advantage

Signature Advantage

Bulletin Board

Your cash summary

Your investments


MILLION(S)

MAY08

AUG09

DEC10

MAR12

MAY13

Total 100.0%


0.0

0.5

1.1

1.7

2.3

2.9

Short-term gains 14.54 14.54

Long-term gains 28,614.74 28,614.74

4 of 25

This section is a summary of realized gains and

losses for this statement period. These figures

do not include transactions which cost

information is unknown or incomplete. This

section is included for your convenience, based

on information provided by you or known to NFS

at the time of this statement.


T1F141631

Your realized Your realizedgains and losses gains and losses

this month ($) this year ($)

Realized Gain/Loss Information



Signature Advantage

Net short term gains and losses $14.54 $14.54

Net long term gains and losses $28,614.74 $28,614.74

Total net gains and losses on youraccount $28,629.28 $28,629.28

Your monthly statement for May, 2013 You are here

Signature Advantage

Signature Advantage

Your realized Signature Advantage gains and losses


Bulletin Board

Your cash summary

Your investments



(continued)

Taxable dividends 2,740.13 15,172.60

Long-term capital gains 0.00 2.78

5 of 25


T1F141631

For thismonth ($) Year to date ($)



Signature Advantage

Total taxable earnings $2,740.13 $15,175.38

Total earnings on your account $2,740.13 $15,175.38


Signature Advantage

Signature Advantage

Taxable earnings

Earnings on your Signature Advantage account


Bulletin Board

Your cash summary

Your investments



(continued)

6 of 25

Every business day, SunTrust automaticallyinvests (sweeps) any cash in your

account into your selected MoneyMarket Mutual Fund. Then, as cash is requiredto cover activity in your account, funds aremoved from your money market mutual fund asneeded. This keeps the maximum amount ofcash invested at all times.

* isprovided for your information and includesaccounts held at SunTrust Banks, Inc. and NFS(member SIPC and NYSE).

This statement reports both cash and investment activity from 05/01/13 through 05/31/13.


T1F141631

How Yoursweep account works



SignatureAdvantage

Your Signature Advantage cash summary


Signature Advantage

deposits from investments $64,433.69

deductions for investments ($2,625.98 )

Core investment option cash $100,620.43

Opening cash balance $38,812.72

Total amounts added $64,433.69

Total amounts deducted ($2,625.98 )

Closing cash balance $100,620.43

Cash holdings


Summary of cash activity

Your cash summary*Signature Advantage

Plus

Less

Bulletin Board


Your investments


Your cash summary

Signature Advantage

Dividends earned on your money marketmutual fund cash sweep investment duringthis statement period are paid at thebeginning of the next month and willappear on your next account statement.

7 of 25

- below lists all cash activity in your account in date order.This includes any investment and checking activity which affects your cash.In the first column of this section:

CHK identifies checking activitiesINV identifies investment activities

INV May 20 You Sold Phillips 66 Com Ex-Div Date 05/16/13Record Date 05/20/13 Payable Dte 06/03/13@ 63.7300 Lt Gain $28,614.74 ST Gain$14.17 64,047.21 102,859.93

INV May 20 IN Lieu of Frx Share Phillips 66 Com ST Gain$0.37 8.41 102,868.34

INV May 21 Portfolio Srvcs. Fee Portfolio Srvcs. Fee (2,399.34 ) 100,469.00

INV May 25 Reinvestment Ft Unit 3580 Int Rt Hedge PortSer 47 Monthly Fee Acct Reinvestment Reinvest@ $11.3323 (226.64 ) 100,242.36

INV May 25 Dividend Received Ft Unit 3412 Inflation HedgeOpportunity Port Ser 12 Monthly Fee Acct Cash 145.05 100,387.41

INV May 25 Dividend Received Ft Unit 3580 Int Rt HedgePort Ser 47 Monthly Fee Acct Reinvestment 232.52 100,619.93

INV May 30 Federated Prime Obligations Trust Sh DividendReceived 0.50 100,620.43


T1F141631

Amounts AmountsClass Date Description added ($) deducted ($) Balance ($)

Apr 30 Opening cash balance $38,812.72

May 31 Closing cash balance $100,620.43


Your investment accountSignature Advantage

Signature Advantage

Details of cash activity in date order Cash dividends on sweep investment

Signature Advantage

Signature Advantage


Important information about your cash activity

Details of cash activity in date order

Your cash summary (continued)Signature Advantage

Signature Advantage

Bulletin Board


Your investments


Your cash summary

8 of 25

cash managementMay 20 Transfer to money market mutual fund 64,055.62

May 21 Transfer from money market mutual fund 2,399.34

May 28 Transfer to money market mutual fund 150.93

May 30 Transfer to money market mutual fund 0.50


T1F141631

Amount or shares Amount or sharesadded to deducted from

money market money marketDate Sweep description mutual fund mutual fund

Total amount $64,207.05 $2,399.34

Closing number of money market mutual fund shares: 100,620.43

An investment in a money market fund isnot a bank deposit and is not insured orguaranteed by the FDIC or any othergovernment agency. Although a moneymarket fund seeks to preserve the value ofyour investment at $1.00 per share, it ispossible to lose money by investing in thefund. Income from Tax-Free andTax-Exempt Funds may be subject to theAlternative Minimum Tax (AMT).


Your investment accountSignature Advantage

Signature Advantage

End of the Signature Advantage bank and brokerage account summary

Signature Advantage


Sweep activity

Your cash summary (continued)Signature Advantage

The cash in your account isinvested automatically in the Federated PrimeObligations.

In the table at the left, amounts transferred to this fundinclude additions of cash to youraccount, such as deposits. Amounts transferred fromthis fund include subtractions of cash from your

account, such as checks.

Bulletin Board


Your investments


Your cash summary

Signature Advantage

Signature Advantage

Signature Advantage

Signature Advantage

9 of 25

Unless otherwise specified in writing,securities, investment and insurance productsoffered through SunTrust Investment Services,Inc.: - are not FDIC insured - are not bank guaranteed - may lose value.

Cash and cash equivalents 3.5%

Equities 76.2%

Fixed income 20.3%

This statement reports on investment activity for the periodMay 1 to May 31, 2013


T1F141631



Your investment account Signature Advantage


Cash and cash equivalents 38,812.72 100,620.43 61,807.71

Equities 398,430.07 335,677.07 (62,753.00 )

Mutual funds 2,455,538.35 2,459,284.69 3,746.34

Total investments $2,892,781.14 $2,895,582.19 $2,801.05

Your asset mix


Signature Advantage

Signature Advantage

Summary of your investments

Your investments *Signature Advantage

Allocations for equities, fixed income, and othercategories may include mutual funds and may benet of short positions. STIS has made assumptionsconcerning how certain mutual funds are allocatedin this representation. The chart may not reflectyour actual portfolio allocation. Before makinginvestment decisions or if your financial situation,investment objectives or restrictions on themanagement of your account have recentlychanged, please consult your adviser at the numberon the first page.

Bulletin Board


Your cash summary


Total 100.0%


Your investments

10 of 25

* Information about your investments and any other investment services or margin accounts is provided by NFS (member

SIPC and NYSE), which carries these accounts and is the clearing broker for SunTrust Investment Services, Inc. (member SIPC). Balances and

margin availability are reflected as of the close of this statement. Margin is subject to change based on the fluctuations in the equity and bond

markets. Please consult your Registered Representative prior to trading to obtain current borrowing availability. For a more complete description,

please see the messages at the end of this statement.

Please review your statement and report any discrepancies immediately. Inquiries or concerns regarding your brokerage

account or the activity therein, should be directed to SunTrust Investment Services, Inc. ("STIS", "we" or "us") at the telephone number and

address reflected on the front of this statement or National Financial Services LLC ("NFS"), who carries your brokerage account and acts as your

custodian for funds and securities that are deposited with NFS by you through STIS, or as a result of transactions NFS processes for your

account, may also be contacted for statement discrepancies. NFS may be called at . Any oral communications regarding

inaccuracies or discrepancies should be reconfirmed in writing to protect your rights, including those under the Securities Investor Protection Act

("SIPA"). When contacting either NFS or STIS, remember to include your entire brokerage account number to ensure a prompt reply. Please notify

our service center promptly in writing of any change of address. Please review your statement and report any discrepancies immediately.

Account statements are deemed to be accurate and are final and binding, unless you specifically notify us otherwise in writing within ten days of

sending. We are authorized to share such customer account information which we may lawfully share with our affiliated entities, including

SunTrust Bank for such purposes as we, in our sole discretion, may deem necessary or appropriate.

. Expected stock split, next dividend payable, and next interest payable information has been provided by third

parties and may be subject to change, Information for certain securities may be missing if not received from third parties in time for printing. NFS

is not responsible for inaccurate, incomplete, or missing information. Please consult us for more information about expected stock split, next

dividend payable, and next interest payable for certain securities.


T1F141631



Customer Service.

(800) 801-9942

Splits, Dividends, and Interest


Signature Advantage

Signature Advantage



Summary of your investments

Your investments (continued)Signature Advantage

Bulletin Board


Your cash summary



Your investments

11 of 25

Federated Prime ObligationsTrust Sh7 Day Yield .01%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 100,620.430 1.000 100,620.43Symbol/Cusip: POLXX

Spdr Gold Tr Gold ShsDividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 305.000 133.920 40,845.60 23,823.74 17,021.86Symbol/Cusip: GLD

Ft Unit 3404 Cap Strength PortSer 15 Semi Annual Fee Acct CashAccount Type: CASH 17,696.000 11.040 195,363.84 162,948.31 32,415.53Symbol/Cusip: 30279L179

The cost basis information we have provided for open-end mutual funds is based on the Average Cost Single Category method and, for all other securities, is based on First In First Out and assumes themethod has been followed consistently for all your investments in the securities. If you used the specific share method to identify lots sold, that identification is not reflected. Cost basis information fordebt securities has not been adjusted for amortization or accretion.


T1F141631

Unrealized EstimatedDescription Quantity Current Current Total cost gain or annualSymbol/Cusip you own price ($) value ($) basis ($)* (loss) ($) income ($)

Core Investment Option

$100,620.43

$100,620.43

Stocks

$40,845.60

Unit Investment



Signature Advantage

Total Core Investment Option

Total cash and cash equivalents

Total Stocks

Signature Advantage


Cash and cash equivalents

Equities

Details of your investments

Your investmentsSignature Advantage

Bulletin Board


Your cash summary


* The abbreviations used in this Column are defined below at the end of the section

Your investments

(continued)

Your Signature Advantage investments.

12 of 25

Ft Unit 3412 Inflation HedgeOpportunity Port Ser 12 MonthlyFee Acct CashAccount Type: CASH 5,162.000 8.570 44,238.34 48,917.18 (4,678.84 )Symbol/Cusip: 30279N522

Ft Unit 3580 Int Rt Hedge PortSer 47 Monthly Fee AcctReinvestmentAccount Type: CASH 5,053.000 10.930 55,229.29 48,653.00 6,576.29Symbol/Cusip: 30290G282

Eaton Vance Gl MacRo AbsoluteRtrn Adv IDividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 2,026.574 10.020 20,306.27 20,594.15 (287.88 )Symbol/Cusip: EGRIX


T1F141631


$294,831.47

$335,677.07 $284,342.23 $51,334.84

Fixed Income Funds



Signature Advantage

Total Unit Investment

Total equities

Signature Advantage


Equities (continued)

Mutual funds

Details of your investments (continued)


Bulletin Board


Your cash summary


Your investments

(continued)

13 of 25

Fidelity Advisor FL Rate HighInc Cl AEstimated Yield 2.89%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 8,058.231 10.010 80,662.89 76,947.35 3,715.54 2,335.37Symbol/Cusip: FFRAX

Franklin Income Class AEstimated Yield 5.82%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 42,647.555 2.340 99,795.28 104,563.04 (4,767.76 ) 5,817.13Symbol/Cusip: FKINX

Loomis Sayles Bond Retail SharesEstimated Yield 5.37%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 358.330 15.330 5,493.20 5,334.34 158.86 295.12Symbol/Cusip: LSBRX

Loomis Sayles Bond InstlEstimated Yield 5.63%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 4,558.619 15.400 70,202.73 65,278.58 4,924.15 3,958.25Symbol/Cusip: LSBDX

PIMCO Commodity Real Return Cl DEstimated Yield 1.41%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 8,218.152 6.000 49,308.91 86,644.13 (37,335.22 ) 696.12Symbol/Cusip: PCRDX


T1F141631






Mutual funds (continued)



Bulletin Board


Your cash summary


Your investments

(continued)

14 of 25

PIMCO Commodity Realreturn StratAEstimated Yield 1.30%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 7,803.890 5.990 46,745.30 57,146.66 (10,401.36 ) 607.87Symbol/Cusip: PCRAX

PIMCO Unconstrained Bond Fund ClAEstimated Yield 0.85%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 11,135.584 11.520 128,281.93 123,791.93 4,490.00 1,091.21Symbol/Cusip: PUBAX

Templeton Global Bond Class AEstimated Yield 5.43%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 6,498.245 13.320 86,556.62 84,269.11 2,287.51 4,706.03Symbol/Cusip: TPINX


T1F141631


$587,353.13 $19,507.10

Equity Funds



Signature Advantage

Total Fixed Income Funds

Signature Advantage





Bulletin Board


Your cash summary


Your investments

(continued)

15 of 25

Invesco Global Core Equity FdClass AEstimated Yield 1.73%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 10,111.480 13.910 140,650.69 127,077.50 13,573.19 2,441.92Symbol/Cusip: AWSAX

Invesco Small Cap Value Fund ClADividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 4,905.742 19.710 96,692.17 75,248.12 21,444.05Symbol/Cusip: VSCAX

Alger Spectra Fund Class Cl AEstimated Yield 0.55%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 11,015.560 15.490 170,631.02 113,098.42 57,532.60 945.14Symbol/Cusip: SPECX

Blackrock Global Allocation Cl AEstimated Yield 1.10%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 12,389.415 20.990 260,053.82 192,121.47 67,932.35 2,870.45Symbol/Cusip: MDLOX

Eaton Vance Tax Mang Global DivInc AEstimated Yield 4.07%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 13,105.575 10.610 139,050.15 114,845.22 24,204.93 5,661.61Symbol/Cusip: EADIX


T1F141631









Bulletin Board


Your cash summary


Your investments

(continued)

16 of 25

Federated Prudent Bear FundClass ADividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 20,598.324 3.110 64,060.79 108,900.00 (44,839.21 )Symbol/Cusip: BEARX

Federated Strategic ValueDividend Cl AEstimated Yield 3.28%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 33,032.951 5.480 181,020.57 158,001.88 23,018.69 5,949.23Symbol/Cusip: SVAAX

Hartford Capital Appreciation ClAEstimated Yield 0.56%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 3,820.418 41.340 157,936.08 111,773.34 46,162.74 889.96Symbol/Cusip: ITHAX

Ing Global Real Estate Cl AEstimated Yield 3.88%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 3,473.808 18.420 63,987.54 48,058.72 15,928.82 2,488.64Symbol/Cusip: IGLAX


T1F141631









Bulletin Board


Your cash summary


Your investments

(continued)

17 of 25

MFS Value Class AEstimated Yield 1.54%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 707.495 29.720 21,026.75 17,379.74 3,647.01 325.60Symbol/Cusip: MEIAX

MFS Utilities Class AEstimated Yield 2.63%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 2,404.737 20.200 48,575.69 41,557.02 7,018.67 1,279.68Symbol/Cusip: MMUFX

Oppenheimer Gold & Spec MineralsCl ADividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 107.882 19.850 2,141.46 5,002.81 (2,861.35 )Symbol/Cusip: OPGSX

Oppenheimer Dev Markets Fd ClassAEstimated Yield 0.38%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 4,674.462 35.580 166,317.36 143,415.62 22,901.74 647.04Symbol/Cusip: ODMAX

Rs Value Fund Cl AEstimated Yield 0.94%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 5,869.364 31.090 182,478.53 143,603.52 38,875.01 1,720.90Symbol/Cusip: RSVAX


T1F141631









Bulletin Board


Your cash summary


Your investments

(continued)

18 of 25

Rs Partners Cl ADividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 2,830.347 37.670 106,619.17 80,961.28 25,657.89Symbol/Cusip: RSPFX

Guggenheim Managed Futures StratCl ADividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 360.333 21.580 7,775.99 9,520.00 (1,744.01 )Symbol/Cusip: RYMTX

Van Eck Global Hard Assets ClassAEstimated Yield 0.56%Dividend Option ReinvestCapital Gain Option ReinvestAccount Type: CASH 1,441.654 43.640 62,913.78 53,244.86 9,668.92 354.65Symbol/Cusip: GHAAX


T1F141631


$1,871,931.56 $25,574.82

$2,459,284.69 $2,168,378.81 $290,905.88 $45,081.92

$2,895,582.19 2,452,721.04 342,240.72 $45,081.92



Signature Advantage

Total Equity Funds

Total mutual funds

Signature Advantage

Total investments


Signature Advantage

Signature Advantage




Bulletin Board


Your cash summary


Your investments

(continued)

19 of 25

May 20 Cash Phillips 66 Com Ex-Div Date05/16/13 Record Date 05/20/13Payable Dte 06/03/13 @ 63.7300Lt Gain $28,614.74ST Gain $14.17 1,005.000 63.73 64,047.21 35,418.30 28,628.91

Apr 30 Cash PIMCO Unconstrained Bond Fund ClA 0.000 78.56

May 01 Cash Fidelity Advisor FL Rate HighInc Cl A 0.000 176.23

May 01 Cash MFS Utilities Class A 0.000 84.03

May 03 Cash Franklin Income Class A 0.000 471.16

May 17 Cash Templeton Global Bond Class A 0.000 259.17

May 22 Cash Eaton Vance Tax Mang Global DivInc A 0.000 470.24

May 25 Cash Ft Unit 3412 Inflation HedgeOpportunity Port Ser 12 MonthlyFee Acct Cash 0.000 145.05

May 25 Cash Ft Unit 3580 Int Rt Hedge PortSer 47 Monthly Fee AcctReinvestment 0.000 232.52

May 28 Cash Loomis Sayles Bond Retail Shares 0.000 22.59

May 28 Cash Loomis Sayles Bond Instl 0.000 305.92

May 30 Cash Federated Prime ObligationsTrust Sh Dividend Received 0.000 0.50


T1F141631

Quantity RealizedSettlement Account bought Total Cost gain ordate type Description or sold Price ($) Amount ($) basis ($)* (loss) ($)

$64,047.21



Signature Advantage

Total securities sold

Signature Advantage


Securities you sold

Dividends/interest/capital gains

Details of investment activityYour investmentsSignature Advantage

Bulletin Board


Your cash summary


* The abbreviations used in this Column are defined below at the end of the section

Your investments

(continued)

Your Signature Advantage investments.

20 of 25

May 31 Cash Federated Strategic ValueDividend Cl A 0.000 494.16

Apr 30 Cash ReinvestmentPIMCO Unconstrained Bond Fund ClA Reinvest @ $11.590 6.778 (78.56 )

May 01 Cash ReinvestmentFidelity Advisor FL Rate HighInc Cl A Reinvest @ $10.030 17.570 (176.23 ) 176.23

May 01 Cash ReinvestmentMFS Utilities Class A Reinvest@ $21.190 3.966 (84.03 ) 84.03

May 03 Cash ReinvestmentFranklin Income Class A Reinvest@ $2.350 200.494 (471.16 ) 471.16

May 17 Cash ReinvestmentTempleton Global Bond Class AReinvest @ $13.690 18.931 (259.17 ) 259.17

May 20 Cash IN Lieu of Frx SharePhillips 66 ComST Gain $0.37 (0.132 ) 8.41 8.04 0.37

May 21 Cash Portfolio Srvcs. FeePortfolio Srvcs. Fee 0.000 (2,399.34 )


T1F141631


$2,740.13



Signature Advantage

Total dividends/interest/capital gains

Signature Advantage


Dividends/interest/capital gains (continued)

Other

Details of investment activity (continued)Your investmentsSignature Advantage

Bulletin Board


Your cash summary


Your investments

(continued)

21 of 25

May 22 Cash ReinvestmentEaton Vance Tax Mang Global DivInc A Reinvest @ $10.850 43.340 (470.24 ) 470.24

May 25 Cash ReinvestmentFt Unit 3580 Int Rt Hedge PortSer 47 Monthly Fee AcctReinvestment Reinvest @ $11.3323 20.000 (226.64 ) 226.64

May 28 Cash ReinvestmentLoomis Sayles Bond Retail SharesReinvested @ $15.43 As of05/28/13 1.464 (22.59 ) 22.59

May 28 Cash ReinvestmentLoomis Sayles Bond InstlReinvested @ $15.49 As of05/28/13 19.750 (305.92 ) 305.92

May 31 Cash ReinvestmentFederated Strategic ValueDividend Cl A Reinvest @ $5.560 88.878 (494.16 ) 494.16


T1F141631


($4,979.63 )



Signature Advantage

Total other

Signature Advantage


Other (continued)

Details of investment activity (continued)Your investmentsSignature Advantage

Bulletin Board


Your cash summary


Your investments

(continued)

22 of 25

Description Fee Amount

Fee calculated by NFS $2,371.56 Billing Period 06/01/2013 - 06/30/2013 Average Annualized Fee 0.99%

Fee for this Account $2,371.56 Average Daily Balance $2,929,315.35

Number Billing Days/365 030/365 Fee to be debited $2,371.56


T1F141631





Management Fee - Notification of Automatic Debit

Debit NotificationYour investmentsSignature Advantage

The fee was calculated by NFS based on certain information provided by the Adviser. NFS processes the fee for the Adviser but does not verify the accuracy of the information. Average

Annualized Fee represents an annualized average of your account fee percentage and/or asset class fee percentage as disclosed in your client fee schedule. You are responsible for verifying

the accuracy of any fee charged by the Adviser.

This notification of an automatic debit is to keep you informed of the activity in your account. This is not an invoice; your account will be debited within 30 days of this statement. If you

have any questions regarding the fee, please contact your investment adviser representative.

Bulletin Board


Your cash summary


Your investments

(continued)

-

23 of 25

Disallowed Loss.


T1F141631

D

Glossary


Signature Advantage

End of the Signature Advantage investments

Signature Advantage


Footnotes and cost basis information

Your investments (continued)Signature Advantage

NFS will report certain cost basis and holding period information to you and to the IRS on your annual Form 1099-B as required or allowed by law, but NFS-provided cost basis, realized gain and loss, and holding periodinformation may not reflect all adjustments necessary for your tax reporting purposes. Taxpayers should verify such information against their own records when calculating reportable gain or loss resulting from a sale,redemption, or exchange. While NFS must meet IRS requirements with respect to certain information required to be reported to the IRS, NFS is not responsible for your use of this information in meeting your federal,state, and other tax obligations. NFS makes no warranties with respect to, and specifically disclaims any liability arising out of a customer's use of, or any tax position taken in reliance upon, such information. Unlessotherwise specified, NFS determines cost basis at the time of sale based on the average cost-single category (ACSC) method for open-end mutual funds and based on the first-in, first-out (FIFO) method for all othersecurities. Customers should consult their tax advisors for further information.

For the specific share identification cost basis method, appropriate instructions must be given in the timeframe specified by IRS regulations. For shares that are subject to IRS cost basis reporting requirements, theinformation reported on your official 1099-B form will reflect a specific identification. If your official 1099-B form does not show cost basis information, the following limitations may apply. If specific shares were selectedmanually rather than electronically, if some or all of the tax lots a customer specified do not correspond with NFS records, or if a customer used the specific share identification method before such method could betracked by NFS systems, then cost basis and gain (loss) information displayed here for such transactions will be based on the first-in, first-out (FIFO) method. Affected customers will need to refer to their tradeconfirmation for the shares (tax lots) they specified and calculate their gain (loss) accordingly. Additionally, all cost basis and realized and unrealized gain (loss) information based on the first-in, first out method may needto re-calculated to remove the effect of any tax lots that were specifically identified and allocated to other sales. For investments in partnerships, NFS does not make any adjustments to cost basis information as thecalculation of basis in such investments requires supplemental information from the partnership on its income and distributions during the period you held your investment. Partnerships usually provide this additionalinformation on a Form K-1 issued by April 15th of the following year.

When you sell shares at a loss and buy additional shares of the same security within 30 days before or after the sale, the loss is disallowed for tax purposes (this is also know as a wash sale). NFSautomatically adjusts your cost basis in the event of a wash sale. If you hold shares of the same security in more than one account, the combined activities could result in a disallowed loss that is not accounted for onyour statement. A disallowed loss is added to the cost basis of the new acquisition.

This may not reflect all of your Realized gain/loss because of incomplete Cost Basis information.

Adjusted cost basis reflects any cumulative original issue discount, premium, or acquisition premium, and it assumes such amounts were amortized by the taxpayer over the life of the security from acquisition datethrough disposition date. For securities still held, maturity date was used instead of disposition date. Premium amortization was calculated using the yield-to-maturity method. Acquisition premium was calculated using theratable accrual method. If applicable, adjusted cost basis reflects market discount accretion which was calculated using the straight-line method and was recognized at disposition date. Gain/loss displayed for thistransaction was based on cost basis as adjusted for premium and discount as stated above and does not reflect any losses disallowed because of wash sales (if applicable). The adjusted cost basis may not reflect alladjustments necessary for tax reporting purposes and may also not apply if you are using an alternative amortization calculation method. Refer to IRS Publication 550, Investment Income and Expenses, for additional

information.

Bulletin Board


Your cash summary


- If you have sold securities under the short sale rule, we have, in accordance with regulations, segregated the proceeds from such transactions in your Short Account. Any market increases or decreases from the original saleprice will be marked to the market and will be transferred to your Margin Account on a weekly basis.

- The total Market Value has been calculated out to 9 decimal places; however, the individual unit price is displayed at 5 decimal places. The Total Market Value represents prices obtained from various sources, may be impacted by thefrequency in which such prices are reported and such prices are not guaranteed. Prices received from pricing vendors are generally based on current market quotes, but when such quotes are not available the pricing vendors use a variety of techniques toestimate value. These estimates, particularly for fixed income securities, may be based on certain minimum principal amounts (e.g. $1 million) and may not reflect all of the factors that affect the value of a security, including liquidity risk.The prices provided are not firm bids or offers. The Market Value of a security, including those priced at par value, may differ from its purchase price and may not closely reflect the value at which the security may be sold or purchased based on variousmarket factors. Investment decisions should be made only after consulting your broker/dealer.

- When available, the coupon rate of some fixed income securities is divided by the current market value of the fixed income security to create the EY figure and/or the current interest rateor most recently declared dividends for certain securities are annualized to create the EAI figure. EAI and EY are estimates, and the income and yield might be lower or higher. Estimates may include return of principal or capital gains which would renderthem overstated. In addition, EAI is calculated for positions or accounts where dividends are reinvested and not paid as income. EY reflects only the income generated by an investment; not changes in prices which fluctuate. These figures are based onmathematical calculations of available data, and have been obtained from information providers believed to be reliable, but no assurance can be made as to accuracy. Since the interest and dividend rates are subject to change at any time, and may beaffected by current and future economic, political and business conditions, they should not be relied on for making investment, trading decisions, or tax decisions.


Your investments

Short Account Balances

Market Value

Estimated Yield ("EY") and Estimated Annual Income ("EAI")

Total of

Section A

Total of

Section B

24 of 25


T1F141631

Ref no. Date Amount

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

Ref no. Date Amount

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$



Section A

Deposits and credits added

Section B

Checks and withdrawals deducted

Signature Advantage

Check to see if the balancein your records is the sameas the closing cash balancein this statement. If it is notgo to Step 2.

In your records, includethe items that appear onthis statement that youhave not recorded, suchas ATM transactions,automatic credits, debits,interest or dividends.

In the columns at the right,list the amounts that havebeen added to or deductedfrom your account since thedate of this statement.

Use this column to balance the cashin your account

Closing cashbalance of your

account $100,620.43

Add thetotal fromSection A +$

Subtract thetotal fromSection B -$

This amount $should be thesame as the amountshown in yourown records


Step 1.Check your records

Step 2.Update your records

Step 3. List amounts

Step 4. Balance your statement

Balancing your accountSignature Advantage

Signature Advantage

Signature Advantage

Bulletin Board


Your cash summary

Your investments


25 of 25


T1F141631



Signature Advantage

Important Information


Bulletin Board


Your cash summary

Your investments


This statement includes all trades made on or before theclosing date of this statement and serves as confirmation of anypurchases that result from any automatic reinvestmenttransactions during the statement period.

("EFT"), telephone us at (800) 874-4770 or write usat the address appearing on the front of your statement. If youthink your statement is wrong or if you need more informationabout a transfer on the statement, we must hear from you nolater than 60 days after we sent you your FIRST statement onwhich the error or problem appeared. (1) Give us your nameand account number as well as the dollar amount of thesuspected error. (2) Describe the error or transfer in question,why you believe there is an error or why you need moreinformation (such as type of error and date of suspected error).We will investigate your complaint and will correct any errorpromptly. If it takes more than 10 days to do this, we will credityour account for the amount you think is in error, so you willhave use of the money while we complete the investigation. Ifwe ask you to put your complaint in writing and we do notreceive it within in 10 business days, we may not credit youraccount.

. Customer free credit balances arenot segregated and may be used in NFS business, subject tothe limitations of 17 CFR Section 240.15c3-2 under theSecurities and Exchange Act of 1934. You have the right toreceive from NFS in the course of normal business operations,subject to open commitments in any of your brokerageaccounts, any free credit balances to which you are entitled orany fully paid securities to which you are entitled and anysecurities purchased on margin upon full payment of anyindebtedness to NFS. Interest on free credit balances awaitingreinvestment may be paid out at rates that may vary withcurrent short-term money market rates and/or your brokerageaccount balances, set at the discretion of us and /or NFS.

. Account holders receivingpayments in lieu of qualified dividends may not be eligible toreceive credit adjustments intended to help cover additionalassociated federal tax burdens. NFS reserves the right to denythe adjustments to any account holder and to amend orterminate the credit adjustment program.

. Shares creditedto your brokerage account resulted from transactions effectedas agent by either: 1) us for your investment account, or 2)through the Depository Trust Company (DTC) dividendreinvestment program. For STIS effected transactions, the timeof the transactions, the exchange upon which thesetransactions occurred and the name of the person from whomthe security was purchased will be furnished upon writtenrequest. NFS may have acted as market maker in effectingtrades in 'over-the-counter' securities.

of NFS is available for your personalinspection at its office or a copy of it will be mailed to you uponyour written request.

. If we no longer provide your Signature

Advantage statement, NFS will mail statements to customerswho have had transactions that affect their cash balances orsecurity positions held in their brokerage accounts during thelast monthly reporting period. Please keep these statementsfor your records, as they will help you prepare your income taxreturns.

In connection with access to, purchase of,and/or maintenance of positions in mutual funds and otherinvestment products ("funds"), your introducing broker dealerand/or NFS may receive the sales loads and 12b-1 feesdescribed in the prospectus as well as additional compensation,paid by the funds, their investment advisors or affiliates.Additional information about the source(s) and amount(s) ofcompensation as well as other remuneration received by yourintroducing broker dealer and/or NFS will be furnished to youupon written request. At time of purchase fund shares may beassigned a load, transaction fee or no transaction fee status. Attime of sale, any fees applicable to your transaction will beassessed based on the status assigned to the shares at time ofpurchase.

. If you have applied for margin privileges and beenapproved, you may borrow money from NFS in exchange forpledging the assets in you account as collateral for anyoutstanding margin loan. The amount you may borrow is basedon the value of securities in your margin account, which areidentified on your statement. If you have a margin account, thisis a combined statement of your margin account and specialmemorandum account other than your non-purpose marginaccount maintained for you under Section 220.5 of Regulation Tissued by the Board of Governors of the Federal Reserve Board.The permanent record of the separate account, as required byRegulation T, is available for your inspection upon request.

. All transactions are subject to theconstitution, rules, regulations, customs, usages, rulings andinterpretations of the exchange market and its clearing house, ifany, where the transactions are executed, and of the New YorkStock Exchange (NYSE) and of the Financial Industry RegulatoryAuthority ( FINRA ). The FINRA requires that we notify you inwriting of the availability of an investor brochure that includesinformation describing FINRA Regulation's BrokerCheckProgram ("Program"). To obtain a brochure or more informationabout the Program or FINRA Regulation, contact the FINRARegulation BrokerCheck Program Hotline at (800) 289-9999 oraccess the FINRA's web site at www.finra.org.

requires that we and NFS allocate betweenus certain functions regarding the administration of yourbrokerage account. The following is a summary of the allocationservices performed by us and NFS. A more completedescription is available upon request.

SunTrust Investment Services, Inc. ("STIS")and its clearing firm, National Financial Services LLC (NFS) areparties to a clearing agreement. With Respect to the functionsthat STIS and NFS perform for your brokerage account, thefollowing is a summary of the roles and responsibilitiesallocated between STIS and NFS. A more complete description

is available upon .

(1) obtaining and verifying account information anddocumentation; (2) opening, approving and monitoring youraccount; (3)acceptance of orders and other instructions fromyou regarding your account, and for transmitting promptly andaccurately those orders and instructions to NFS with respect toyour account; (4) determining the suitability of investmentrecommendations and advice; (5) operating in compliance withall applicable laws, rules, and regulations relating to STIS' ownoperations, supervising STIS' sales representatives and itsother personnel, and the supervision of certain transactions andother activity in your account; (6) maintaining the requiredbooks and records for the services STIS performs; and (7)investigating and responding to any questions or complaintsyou have about your account, confirmations, your periodicstatement, or any other matter related to your account.

(1) execute, clear and settle ordersor transactions processed through NFS by STIS; (2) prepareand send transaction confirmations and periodic statements ofyour account (unless STIS has undertaken to do so) (Certainpricing and other information may be provided by STIS orobtained from third parties, which has not been verified byNFS.); (3) custody or safeguarding of funds and securitiesdelivered to NFS on your behalf or received by NSF on yourbehalf; (4) follow STIS' instructions with respect to orders ortransactions, and the receipt and delivery of funds andsecurities for your account; and (5) extend margin credit forpurchasing or carrying securities on margin, if applicable. Youand STIS are responsible for ensuring that your margin accountis in compliance with federal, industry, and NFS margin rulesand for being advised of margin requirements. NFS shallmaintain the required books and records for the services NFSperforms. At the direction of STIS, listed and over-the-counterorder flow in equity securities may be transmitted to SunTrustRobinson Humphrey, Inc. ("STRH"), at $2.00 per order payableto STRH. (see your customer agreement for more detail) STISand STRH are affiliated companies.

Each transaction confirmation previouslydelivered to you contains full information about commissionsand other charges. If you require further information, pleasecontact your broker/dealer. Assignments of American andEuropean-style options are allocated among customer shortpositions pursuant to a random allocation procedure, adescription of which is available upon request. Short positions inAmerican-style options are liable for assignment at any time.The writer of a European-style option is subject to exerciseassignment only during the exercise period. You should adviseyour broker/dealer promptly of any material change in yourinvestment objectives or financial situation. Splits, Dividendsand Interest, Expected stock split, next dividend payable, andnext interest payable information has been provided by thirdparties and may be subject to change. Information for certainsecurities may be missing if not received from third parties intime for printing. NFS is not responsible for inaccurate,

incomplete, or missing information. Please consult yourbroker/dealer for more information about expected stock split,next dividend payable, and next interest payable for certainsecurities.

A summary ofretirement contributions/distributions is displayed for you in theactivity summary section of your statement. Income reporting,NFS reports earnings from investments in Traditional IRA's,Rollover IRA's, SEP-IRA's and, Keoghs as tax-deferred income.Earnings from Roth IRA's are reported as tax-free income, sincedistributions may be tax-free after meeting the 5 year agingrequirement and certain other conditions.

areprotected in accordance with the Securities Investor ProtectionCorporation ("SIPC") up to $500,000. The $500,000 totalamount of SIPC protection is inclusive of up to $250,000protection for claims for cash, subject to periodic adjustmentsfor inflation in accordance with terms of the SIPC statute andapproval by SIPC's Board of Directors. NFS also has arrangedfor coverage above these limits. Neither coverage protectsagainst a decline in the market value of securities, nor doeseither coverage extend to certain securities that are consideredineligible for coverage.Annuities and other products purchased through but not held inyour Brokerage Account do not receive the SIPC protection oradditional coverage associated with your Brokerage Account,even though these products may be reflected on yourBrokerage Account statements. For more details on SIPC, or torequest a SIPC brochure, visit www.sipc.org or call1-202-371-8300.

In case of errors or questions about your electronictransfers

On Free Credit Balances

Credit Adjustment Program

Equity Dividend Reinvestment Customers

A financial statement

Statement Mailing

Loads and Fees.

Margin

NYSE and FINRA

FINRA Rule 4311

Statement of SunTrust Investment Services, Inc. and NFS'Responsibilities

requestSunTrust Investment Services, Inc. Is responsible for thefollowing:

NFS is responsible for and shall perform the followingtasks at STIS' direction:

Options Customers,

Retirement Contributions / Distributions,

Securities in your brokerage accounts carried by NFS

Portfolio OverviewACNP Report Set ACNP

Period Ending: 5/31/2013

Portfolio Inception Date: 2/28/2006

Asset Allocation

CategoryCurrent

PercentageCurrent

Value

Cash & Equivalents 11.7% $319,121

Fixed Income 31.3% $854,735

Equity 50.4% $1,376,001

Alternative 6.7% $182,164

Total Portfolio Value 100.0% $2,732,021

Portfolio Value Vs Cumulative Net Investment

Portfolio Value Cumulative Net Investment

$0.00

$500,000.00

$1,000,000.00

$1,500,000.00

$2,000,000.00

$2,500,000.00

2/28/2006 6/30/2007 12/31/2008 6/30/2010 12/31/2011 5/31/2013

Components of Change

BEGINNING VALUE

Net Contributions

Capital Appreciation

Income

Management Fees

Other Expenses

Change in Accrued

Transfers

ENDING VALUE

INVESTMENT GAIN

Current Quarter

$2,755,210

$0

($30,905)

$12,840

($4,234)

($244)

($646)

$0

$2,732,021

($23,188)

Year to Date

$2,641,246

$0

$67,670

$33,712

($9,785)

($527)

($293)

$0

$2,732,021

$90,776

Since Inception

$0

$2,199,600

$141,854

$502,918

($106,055)

($3,212)

($3,084)

$2,058

$2,732,021

$532,421

Current Quarter Year to Date

Since Inception

Your Portfolio (0.8%) 3.4% 3.5%

All returns are TWR, net of fees. Returns for greater than 1 year are annualized.

This data is gathered from what is believed to be reliable sources, but we cannot guarantee its accuracy. Please use your brokerage statements as an accurate reflection of your portfolio. 1

Calendar Year Performance Review

ACNP Report Set5034A Thoroughbred Lane

Brentwood, TN 37027

Description 2012 2011 2010 2009 2008 2007 *2006

Beginning Value 2,460,302. 34 2,195,986. 30 1,988,124. 46 1,685,614. 27 1,738,598. 83 1,424,752. 85 0. 00

Contributions 187. 54 250,225. 00 0. 00 0. 00 500,000. 00 150,000. 00 1,800,400. 52

Withdrawals 0. 00 0. 00 0. 00 0. 00 0. 00 0. 00 -500,000. 00

Transfers 42. 77 1,050. 64 0. 00 0. 00 0. 00 0. 00 964. 25

Unrealized Gain (Loss) 101,164. 89 -47,539. 93 116,251. 40 237,939. 87 -480,429. 03 46,198. 27 74,982. 54

Realized Gain (Loss) 12,520. 29 -8,457. 87 32,515. 78 21,965. 58 -118,414. 34 81,316. 07 523. 80

Dividend Income 63,742. 57 65,156. 91 60,237. 50 54,021. 96 54,840. 01 30,512. 76 23,912. 00

Interest Income 26,630. 49 26,620. 48 15,796. 93 321. 48 3,750. 77 15,254. 84 28,625. 32

Management Fees -21,788. 34 -20,354. 50 -16,573. 61 -11,545. 97 -11,482. 00 -8,409. 77 -6,115. 15

Other Expenses -817. 46 -1,091. 88 -747. 44 -26. 81 -1. 36 0. 00 0. 00

Change in Accrued -739. 35 -1,292. 81 381. 28 -165. 92 -1,248. 61 -1,026. 19 1,459. 57

Ending Value 2,641,245. 74 2,460,302. 34 2,195,986. 30 1,988,124. 46 1,685,614. 27 1,738,598. 83 1,424,752. 85

Investment Gain 180,755. 86 14,091. 04 207,861. 84 302,510. 19 -552,984. 56 163,845. 98 124,352. 33

Time Weighted (gross) 8. 26 1. 97 11. 35 18. 71 (25. 68) 11. 75 7. 34

Time Weighted (net) 7. 35 1. 10 10. 46 17. 95 (26. 15) 11. 16 6. 98S&P 500 TR 15. 25 2. 12 15. 05 26. 45 (37. 00) 5. 50 12. 50MSCI EAFE (Foreign) 13. 55 (14. 81) 4. 90 27. 75 (45. 09) 8. 61 16. 77MSCI Emerging Markets 15. 15 (20. 40) 16. 36 74. 49 (54. 48) 36. 49 16. 70Barcap Agg. Bond (Bond Market) 4. 23 7. 86 6. 56 5. 93 5. 24 6. 96 3. 98ACNP - Target 10. 36 0. 32 .. .. .. .. ..

* Return since inception date of 02/28/2006

Calendar Year Performance Review

ACNP Report Set

All returns NET of fees unless otherwise indicated. Past performance is no guarantee of future results."Since Inception" returns denote account inception with Olimpio Neu & Assoc.

Portfolio Position AnalysisAs of 05/31/2013


Brentwood, TN 37027

ActualUnit Current Cash Cost Cash Current Dollar Net

Description Weight Symbol Quantity Cost Price Invested Basis Income Value Gain (IRR%)

ACNP 22669694 501 - ONACash & Equivalents

Cash & EquivalentsSchwab Money Market Fund 8. 7% MMF 237,890. 11 237,890. 11 0. 00 237,890. 11

Fixed IncomeShort Term Bonds

Vanguard Short Term Bond 1. 3% BSV 425 80. 430 80. 580 34,182. 78 34,182. 78 1,576. 95 34,246. 50 63. 72 4. 92

Int. Term BondsDoubleline Core Fixed 5. 3% DBLFX 13,019. 358 11. 137 11. 210 145,000. 00 145,000. 00 6,214. 95 145,947. 00 947. 00 7. 30PIMCO Corporate Opportunity Fun 2. 5% PTY 3,743 11. 086 18. 270 47,743. 81 41,493. 57 52,707. 32 68,384. 61 20,640. 80 216. 06Templeton Global Bond 4. 0% TPICZ 8,293. 473 12. 198 13. 320 96,011. 17 101,166. 09 27,614. 69 110,469. 06 14,457. 89 78. 29

11. 9% 11. 481 288,754. 98 287,659. 66 86,536. 96 324,800. 67 36,045. 69

13. 1% 12. 631 322,937. 76 321,842. 44 88,113. 91 359,047. 17 36,109. 41

EquityLarge Cap Stocks

American Century Equity Income 2. 1% TWEIX 6,457. 236 6. 727 8. 720 42,757. 14 43,438. 16 10,349. 13 56,307. 10 13,549. 96 43. 20First Trust Value Line Dividend Idx 6. 9% FVD 9,500 18. 665 19. 740 177,312. 85 177,312. 85 480. 15 187,530. 00 10,217. 15 11. 40Schwab US Broad Mkt 7. 7% SCHB 5,300 37. 652 39. 550 199,555. 40 199,555. 40 439. 02 209,615. 00 10,059. 60 9. 85

16. 6% 19. 772 419,625. 39 420,306. 41 11,268. 30 453,452. 10 33,826. 71

Small Cap StocksBuffalo Small Cap 1. 3% BUFSX 1,089. 579 21. 077 33. 120 26,034. 73 22,964. 91 1,975. 66 36,086. 86 10,052. 13 58. 47Royce Micro Cap Svc 0. 9% RMCFX 1,683. 755 12. 392 15. 270 22,735. 33 20,865. 71 3,549. 36 25,710. 94 2,975. 61 53. 31Schwab U.S. Small Cap 3. 3% SCHA 2,000 42. 044 44. 520 84,088. 00 84,088. 00 0. 00 89,040. 00 4,952. 00 5. 89

5. 5% 26. 799 132,858. 06 127,918. 62 5,525. 02 150,837. 80 17,979. 74

Intl Developed StocksMatthews Asia Dividend 1. 3% MAPIX 2,273. 841 14. 255 15. 850 31,141. 66 32,413. 39 5,337. 11 36,040. 38 4,898. 72 40. 18Mutual Global Discovery A 1. 4% TEDIX 1,215. 055 25. 281 31. 950 31,509. 80 30,717. 37 11,873. 01 38,821. 01 7,311. 21 49. 15

2. 7% 18. 095 62,651. 46 63,130. 76 17,210. 12 74,861. 39 12,209. 93


ACNP Report Set



ACNP 22669694 501 - ONAEquity

Emerging Market StocksSchwab Emerging Markets 2. 8% SCHE 3,100 25. 944 24. 700 80,426. 18 80,426. 18 2,423. 78 76,570. 00 (3,856. 18) -3. 24

27. 7% 21. 208 695,561. 09 691,781. 97 36,427. 22 755,721. 29 60,160. 20

AlternativeAlternatives

Central Fund of Canada 3. 0% CEF 5,125 21. 976 15. 960 112,626. 75 112,626. 75 66. 00 81,795. 00 (30,831. 75) -38. 01

Large Cap StocksKayne Anderson Energy Fd 2. 3% KYE 2,150 23. 305 29. 860 50,105. 26 50,105. 26 11,064. 00 64,199. 00 14,093. 74 48. 86

5. 3% 22. 369 162,732. 01 162,732. 01 11,130. 00 145,994. 00 (16,738. 01)

54. 9% 17. 994 1,419,120. 97 1,414,246. 53 135,671. 13 1,498,652. 57 79,531. 60

ACNP 12907297 501- CapstoneCash & Equivalents

Cash & EquivalentsSchwab Money Market Fund 3. 0% MMF 81,230. 50 81,230. 50 0. 00 81,230. 50

Fixed IncomeShort Term Bonds

American Express Corp 0. 6% 0258M0CY3 15,000 113. 626 101. 413 17,043. 90 17,043. 90 3,285. 00 15,211. 91 (1,831. 99) 9. 4308/20/2013 7.30%

Accrued Income 305. 51Morgan Stanley Glbl Sb Nt 0. 8% 61748AAE6 20,000 105. 494 102. 747 21,098. 80 21,098. 80 1,900. 00 20,549. 40 (549. 40) 6. 7904/01/2014 4.75%

Accrued Income 158. 33Federal Farm Cr Bk 0. 9% 31331GTJ8 25,000 101. 180 102. 130 25,295. 00 25,295. 00 1,968. 78 25,532. 50 237. 50 8. 7304/17/2014 2.625%

Accrued Income 80. 69JPM Chase Sr. Nt, 4.65% 0. 5% 46625HHN3 14,000 105. 610 103. 790 14,785. 40 14,785. 40 0. 00 14,530. 60 (254. 80) 0. 1706/01/2014 4.65%

Accrued Income 325. 50American Express 0. 3% 0258M0CZ0 7,000 106. 098 105. 527 7,426. 86 7,426. 86 0. 00 7,386. 89 (39. 97) -0. 2508/25/2014 5.125%

Accrued Income 95. 67


ACNP Report Set



ACNP 12907297 501- CapstoneFixed Income

Short Term BondsExelon Corp Notes 0. 6% 30161NAD3 15,000 110. 059 107. 767 16,508. 85 16,508. 85 1,837. 50 16,165. 05 (343. 80) 10. 7606/15/2015 4.90%

Accrued Income 339. 23Metlife Inc 0. 6% 59156RAN8 15,000 105. 813 108. 348 15,871. 95 15,871. 95 2,250. 00 16,252. 17 380. 22 17. 7406/15/2015 5.00%

Accrued Income 345. 83Credit Suisse USA 0. 6% 225434AG4 15,000 107. 509 111. 435 16,126. 35 16,126. 35 2,418. 78 16,715. 24 588. 89 19. 1603/02/2016 5.38%

Accrued Income 199. 56CVS Corp SR Nt 0. 6% 126650BE9 15,000 111. 018 115. 296 16,652. 70 16,652. 70 2,756. 28 17,294. 40 641. 70 21. 6808/15/2016 6.13%

Accrued Income 269. 25Anadarko Petro Corp SR Nts 0. 8% 032511AX5 20,000 112. 132 113. 982 22,426. 35 22,426. 35 2,826. 25 22,796. 40 370. 05 19. 6609/15/2016 5.95%

Accrued Income 252. 23Wachovia Corp New 0. 9% 929903CH3 22,000 108. 911 113. 692 23,960. 39 23,960. 39 2,531. 28 25,012. 24 1,051. 85 23. 1910/15/2016 5.63%

Accrued Income 159. 06Valero Energy Corp Bonds 0. 9% 91913YAM2 20,000 113. 166 117. 255 22,633. 20 22,633. 20 2,450. 00 23,451. 00 817. 80 15. 2406/15/2017 6.13%

Accrued Income 565. 85Kimberly Clark 0. 7% 494368BB8 15,000 114. 494 119. 070 17,174. 10 17,174. 10 2,756. 28 17,860. 50 686. 40 22. 0208/01/2017 6.125%

Accrued Income 306. 25Motorola Inc Note Call Make Whol 0. 9% 620076AZ2 20,000 112. 841 115. 954 22,568. 20 22,568. 20 2,400. 00 23,190. 80 622. 60 14. 1511/15/2017 6.00%


9. 7% 109. 064 259,572. 05 259,572. 05 29,380. 15 265,407. 49 2,377. 05

Int. Term BondsPhilips Electronics Notes 1. 0% 500472AB1 22,000 112. 590 117. 933 24,769. 81 24,769. 81 2,587. 50 25,945. 26 1,175. 45 24. 3803/11/2018 5.75%

Accrued Income 281. 88At&T Inc Notes 0. 8% 00206RAM4 18,000 113. 123 118. 232 20,362. 14 20,362. 14 2,016. 00 21,281. 76 919. 62 14. 5605/15/2018 5.60%

Accrued Income 46. 57Bottling Gr 1. 0% 10138MAK1 22,000 110. 797 116. 184 24,375. 37 24,375. 37 2,306. 28 25,560. 48 1,185. 11 23. 9701/15/2019 5.125%



ACNP Report Set



ACNP 12907297 501- CapstoneFixed Income

Int. Term BondsWalgreen 0. 6% 931422AE9 15,000 107. 988 114. 955 16,198. 20 16,198. 20 2,362. 50 17,243. 25 1,045. 05 22. 2201/15/2019 5.25%

Accrued Income 297. 50Time Warner Cable Inc Note 0. 8% 88732JAW8 20,000 104. 591 112. 688 20,918. 20 20,918. 20 2,000. 00 22,537. 60 1,619. 40 18. 1002/01/2020 5.00%

Accrued Income 331. 49United Technologies 0. 8% 913017BV0 20,000 106. 892 102. 550 21,378. 40 21,378. 40 310. 00 20,510. 00 (868. 40) -2. 4906/01/2022 3.10%


4. 9% 109. 404 128,002. 12 128,002. 12 11,582. 28 134,771. 73 5,076. 23

Large Cap StocksDuke Energy Corp Jr. Sub Deb 5.12 0. 7% DUKH 750 25. 860 24. 920 19,394. 95 19,394. 95 0. 00 18,690. 00 (704. 95) -3. 63Goldman Sachs Group Inc Nt 6.50 0. 7% GSJ 725 28. 124 26. 890 20,390. 15 20,390. 15 0. 00 19,495. 25 (894. 90) -4. 39Nextera Energy 0. 7% NEE+F 725 27. 234 26. 050 19,744. 90 19,744. 90 0. 00 18,886. 25 (858. 65) -4. 35Prudential JR Sub Nts 9.00% 0. 7% PHR 755 27. 026 24. 980 20,404. 31 20,404. 31 3,802. 48 18,859. 90 (1,544. 41) 16. 11Stanley Black & Decker Inc 0. 7% SWJ 755 26. 303 25. 930 19,858. 54 19,858. 54 542. 68 19,577. 15 (281. 39) 1. 34

3. 5% 26. 898 99,792. 85 99,792. 85 4,345. 16 95,508. 55 (4,284. 30)

18. 1% 108. 325 487,367. 02 487,367. 02 45,307. 59 495,687. 77 3,168. 98

EquityLarge Cap Stocks

Analog Devices Inc 0. 3% ADI 182 46. 428 45. 930 8,449. 93 8,449. 93 0. 00 8,359. 26 (90. 67) -1. 07Auto Data Processing 0. 5% ADP 214 44. 551 68. 720 9,533. 88 9,533. 88 977. 98 14,706. 08 5,172. 20 72. 28CA Technologies 0. 3% CA 316 24. 666 27. 320 7,794. 56 7,794. 56 79. 00 8,633. 12 838. 56 11. 85Campbell Soup Company 0. 3% CPB 211 35. 670 42. 810 7,526. 46 7,526. 46 727. 96 9,032. 91 1,506. 45 30. 34CenturyLink Inc 0. 2% CTL 144 42. 031 34. 150 6,052. 49 6,052. 49 808. 56 4,917. 60 (1,134. 89) -5. 78ChevronTexaco Corp 0. 5% CVX 109 80. 810 122. 750 8,808. 30 8,808. 30 1,052. 94 13,379. 75 4,571. 45 66. 12Conagra Foods Inc 0. 3% CAG 221 22. 230 33. 690 4,912. 72 4,912. 72 530. 40 7,445. 49 2,532. 77 65. 19ConocoPhillips 0. 4% COP 186 61. 957 61. 340 11,523. 97 11,523. 97 0. 00 11,409. 24 (114. 73) -1. 00Corning Inc 0. 3% GLW 461 11. 506 15. 370 5,304. 46 5,304. 46 117. 56 7,085. 57 1,781. 11 36. 20Engelhard Corp 0. 2% EC 134 52. 887 43. 350 7,086. 83 7,086. 83 871. 52 5,808. 90 (1,277. 93) -6. 08Gannett 0. 3% GCI 406 19. 070 21. 500 7,742. 36 7,742. 36 81. 20 8,729. 00 986. 64 13. 87Genuine Parts Co 0. 8% GPC 286 42. 760 77. 740 12,229. 23 12,229. 23 1,586. 59 22,233. 64 10,004. 41 100. 01Intel Corp 0. 5% INTC 544 23. 735 24. 280 12,912. 09 12,912. 09 1,278. 34 13,208. 32 296. 23 17. 45International Business Machines 0. 6% IBM 82 131. 419 208. 020 10,776. 37 10,776. 37 738. 00 17,057. 64 6,281. 27 70. 42


ACNP Report Set



ACNP 12907297 501- CapstoneEquity

Large Cap StocksKimberly-Clark Corp. 0. 3% KMB 89 62. 021 96. 830 5,519. 83 5,519. 83 760. 95 8,617. 87 3,098. 04 76. 66KLA-Tencor Corp 0. 3% KLAC 156 53. 815 56. 290 8,395. 21 8,395. 21 0. 00 8,781. 24 386. 03 4. 60Linear Technology Corp 0. 2% LLTC 148 31. 668 37. 525 4,686. 93 4,686. 93 367. 04 5,553. 70 866. 77 27. 22Lockheed Martin Corp 0. 3% LMT 66 83. 556 105. 830 5,514. 67 5,514. 67 696. 96 6,984. 78 1,470. 11 39. 16Mattel Incorporated 0. 9% MAT 526 23. 666 44. 750 12,448. 32 12,448. 32 1,762. 10 23,538. 50 11,090. 18 115. 68McDonalds Corp. 0. 6% MCD 181 69. 848 96. 570 12,642. 57 12,642. 57 1,426. 28 17,479. 17 4,836. 60 50. 50Microsoft Corp. 0. 5% MSFT 395 25. 012 34. 900 9,879. 61 9,879. 61 801. 85 13,785. 50 3,905. 89 49. 32Pitney Bowes Nt 0. 7% PBI+B 700 26. 140 25. 410 18,298. 06 18,298. 06 0. 00 17,787. 00 (511. 06) -2. 79PP&L Corp 0. 4% PPL 332 27. 705 29. 700 9,198. 15 9,198. 15 600. 09 9,860. 40 662. 25 14. 18Public Storage 0. 7% PSA+V 775 25. 550 25. 030 19,801. 38 19,801. 38 552. 52 19,398. 25 (403. 13) 0. 79Raytheon Company New 0. 4% RTN 146 58. 107 66. 640 8,483. 67 8,483. 67 787. 67 9,729. 44 1,245. 77 24. 53Shaw Commun Inc Cl B 0. 4% SJR 515 19. 325 22. 300 9,952. 57 9,952. 57 1,473. 35 11,484. 50 1,531. 93 36. 24Sysco Corporation 0. 4% SYY 338 29. 864 33. 800 10,094. 19 10,094. 19 1,074. 84 11,424. 40 1,330. 21 18. 08

11. 6% 32. 503 255,568. 81 255,568. 81 19,153. 70 316,431. 27 60,862. 46

Small Cap StocksB&G Foods Inc 0. 2% BGS 144 29. 010 28. 780 4,177. 46 4,177. 46 83. 52 4,144. 32 (33. 14) 1. 22Cullen Frost Bankers 0. 3% CFR 114 59. 848 64. 350 6,822. 62 6,822. 62 479. 94 7,335. 90 513. 28 15. 10Hubbell Inc Class B 0. 7% HUBB 190 52. 165 100. 430 9,911. 26 9,911. 26 898. 70 19,081. 70 9,170. 44 131. 69IAMGOLD Corp 0. 2% IAG 966 8. 788 5. 280 8,489. 46 8,489. 46 0. 00 5,100. 48 (3,388. 98) -39. 92Meridian Bioscience Inc 0. 3% VIVO 418 21. 877 21. 610 9,144. 38 9,144. 38 79. 42 9,032. 98 (111. 40) -0. 35Northwest Bancsharesinc Com 0. 2% NWBI 352 12. 084 12. 400 4,253. 72 4,253. 72 211. 20 4,364. 80 111. 08 7. 71Peoples United Financial 0. 3% PBCT 631 13. 593 13. 775 8,577. 30 8,577. 30 0. 00 8,692. 03 114. 73 1. 34Scana Corporation New 0. 1% SCG 73 38. 613 50. 440 2,818. 72 2,818. 72 427. 29 3,682. 12 863. 40 45. 76Sensient Technologies 0. 4% SXT 246 30. 632 41. 270 7,535. 57 7,535. 57 622. 38 10,152. 42 2,616. 85 40. 50Techne Corp Common 0. 3% TECH 127 67. 444 66. 510 8,565. 35 8,565. 35 0. 00 8,446. 77 (118. 58) -1. 38TECO Energy Inc 0. 2% TE 301 17. 196 17. 610 5,175. 92 5,175. 92 132. 44 5,300. 61 124. 69 5. 00Tompkins Financial Cp 0. 3% TMP 210 38. 125 41. 540 8,006. 17 8,006. 17 974. 40 8,723. 40 717. 23 14. 48

3. 4% 22. 131 83,477. 93 83,477. 93 3,909. 29 94,057. 53 10,579. 60

Intl Developed StocksABB, Ltd ADR 0. 5% ABB 602 18. 384 21. 790 11,067. 09 11,067. 09 435. 91 13,117. 58 2,050. 49 22. 55Bank Of Montreal 0. 5% BMO 241 58. 675 59. 080 14,140. 71 14,140. 71 340. 18 14,238. 28 97. 57 3. 11Bank Of Nova Scotia 0. 5% BNS 262 45. 943 56. 730 12,037. 11 12,037. 11 1,676. 55 14,863. 26 2,826. 15 39. 89BCE Inc 0. 5% BCE 279 40. 991 44. 680 11,436. 54 11,436. 54 780. 77 12,465. 72 1,029. 18 16. 34BHP Billiton Ltd Adr 0. 2% BHP 71 89. 316 65. 320 6,341. 44 6,341. 44 383. 40 4,637. 72 (1,703. 72) -21. 42Canon ADR 0. 3% CAJ 249 47. 080 34. 280 11,722. 91 11,722. 91 750. 81 8,535. 72 (3,187. 19) -21. 44China Petroleum & Chemical 0. 5% SNP 137 97. 881 101. 810 13,409. 74 13,409. 74 1,140. 50 13,947. 97 538. 23 13. 19


ACNP Report Set



ACNP 12907297 501- CapstoneEquity

Intl Developed StocksEnsco Plc 0. 4% ESV 200 60. 959 60. 170 12,191. 79 12,191. 79 0. 00 12,034. 00 (157. 79) -1. 29HSBC Holdings PLC ADR 0. 3% HBC 140 55. 202 54. 860 7,728. 27 7,728. 27 126. 00 7,680. 40 (47. 87) 1. 01ING Groep Nv 0. 7% ISG 740 20. 141 25. 110 14,904. 07 14,904. 07 2,729. 46 18,581. 40 3,677. 33 75. 68National Grid Adr 0. 4% NGG 199 54. 271 59. 560 10,799. 92 10,799. 92 228. 79 11,852. 44 1,052. 52 11. 98Petrochina Co Ltd ADR 0. 3% PTR 74 133. 067 115. 680 9,846. 95 9,846. 95 0. 00 8,560. 32 (1,286. 63) -13. 07Reed Elsevier Adr 0. 4% RUK 226 35. 378 45. 040 7,995. 34 7,995. 34 231. 83 10,179. 04 2,183. 70 30. 22Siemens AG ADR 0. 4% 826197402 116 100. 863 105. 100 11,700. 16 11,700. 16 697. 08 12,191. 60 491. 44 12. 71Smith & Nephew ADR 0. 3% SNN 123 52. 391 58. 340 6,444. 06 6,444. 06 99. 63 7,175. 82 731. 76 12. 92Transcanada Corp 0. 4% TRP 249 33. 694 45. 850 8,389. 79 8,389. 79 1,272. 97 11,416. 65 3,026. 86 54. 93Unilever Plc Adr New 0. 5% UL 338 31. 304 42. 010 10,580. 91 10,580. 91 735. 21 14,199. 38 3,618. 47 42. 61Westpac Banking ADR 0. 5% WBK 105 124. 383 134. 420 13,060. 24 13,060. 24 459. 08 14,114. 10 1,053. 86 11. 80

7. 7% 44. 541 193,797. 04 193,797. 04 12,088. 17 209,791. 40 15,994. 36

22. 7% 33. 332 532,843. 78 532,843. 78 35,151. 16 620,280. 20 87,436. 42

AlternativeAlternatives

Getty Realty Corp 0. 3% GTY 344 25. 308 20. 960 8,705. 95 8,705. 95 534. 92 7,210. 24 (1,495. 71) -11. 47LTC Properties Inc 0. 3% LTC 226 28. 788 41. 610 6,506. 00 6,506. 00 832. 81 9,403. 86 2,897. 86 60. 73Public Storage Inc 0. 5% PSA 82 92. 379 151. 800 7,575. 09 7,575. 09 959. 40 12,447. 60 4,872. 51 72. 34Senior Housing Pptys Tr 0. 3% SNH 275 21. 633 25. 850 5,948. 95 5,948. 95 1,245. 75 7,108. 75 1,159. 80 38. 45

1. 3% 30. 999 28,735. 99 28,735. 99 3,572. 88 36,170. 45 7,434. 46

45. 1% 104. 942 1,130,177. 29 1,130,177. 29 84,031. 63 1,233,368. 92 98,039. 86

100. 0% 92. 053 2,549,298. 26 2,544,423. 82 219,702. 76 2,732,021. 49 177,571. 46

Prepared by Olimpio Neu & Associates, Inc.Please contact Olimpio Neu & Associates if there are changes in your personal or financial situation or investment objectives or if you wish to impose, add or modify any reasonable restrictions to the management of youraccount. A copy of our current written disclosure statement as set forth in Part II of Form ADV is available for your review upon request.

Asset Class Performance Summary


Brentwood, TN 37027

ActualAsset Class Beginning Ending Investment NetDescription Value Value Gain (TWR)

May 2013

Short Term Bonds 286,059 299,654 (1,344) -0. 45Barcap 1-5 Yr Gov/Credit -0. 49

Int. Term Bonds 538,851 459,572 (23,581) -4. 44Barcap Agg. Bond (Bond Market) -1. 79

Alternatives 127,065 117,965 (8,957) -7. 05

Large Cap Stocks 740,347 929,591 (2,586) -0. 43S&P 500 TR 2. 34

Small Cap Stocks 138,075 244,895 9,579 3. 28Russell 2000 (Small Cap) 4. 00

Intl Developed Stocks 407,092 284,653 (9,994) -3. 57MSCI EAFE (Foreign) -2. 93

Emerging Market Stocks 54,474 76,570 (3,702) -4. 96MSCI Emerging Markets -2. 94

Conservative Alloc. Funds 146,029 0 (895) -0. 61Dow Jones Conservative -0. 06( 04/30/2013 - 05/01/2013 )

Total Portfolio 2,775,113 2,732,021 (43,092) -1. 55

YTD

Short Term Bonds 335,413 299,654 1,449 0. 44Barcap 1-5 Yr Gov/Credit 0. 07

Int. Term Bonds 526,811 459,572 (1,168) -0. 32Barcap Agg. Bond (Bond Market) -0. 92

Alternatives 129,291 117,965 (20,955) -15. 28

Large Cap Stocks 663,651 929,591 79,960 11. 46S&P 500 TR 15. 38

Small Cap Stocks 120,409 244,895 15,522 8. 37Russell 2000 (Small Cap) 16. 46

Asset Class Performance Summary

ACNP Report Set

ActualAsset Class Beginning Ending Investment NetDescription Value Value Gain (TWR)

YTD

Intl Developed Stocks 334,460 284,653 22,855 4. 89MSCI EAFE (Foreign) 6. 12

Emerging Market Stocks 55,419 76,570 (4,647) -6. 58MSCI Emerging Markets -4. 39

Conservative Alloc. Funds 187,734 0 8,063 5. 10Dow Jones Conservative 1. 42( 12/31/2012 - 05/01/2013 )

Total Portfolio 2,641,246 2,732,021 90,776 3. 44

All returns NET of fees unless otherwise indicated. Past performance is no guarantee of future results."Since Inception" returns denote account inception with Olimpio Neu & Assoc.

March 26, 2012

Richard Bergeron, M.D., Ph.D.

Ottawa Health Research Institute

725 Parkdale

Psychiatry

Ottawa, ON K1Y 1K7

Dear Dr. Bergeron:

I am writing to remind you of the attendance requirement for Associate Members. ACNP

associate membership is based, in part, on an assumption that the Associate Member will

be active in the College and will regularly attend annual meetings. In fact, the ACNP By-

laws require that Associate Members attend the ACNP Annual Meeting in order to

remain in good standing. We understand that there are times when it is impossible for

you to make the meeting. Therefore, during your tenure as an Associate Member, you

are permitted up to two absences from the meeting.

In a review of our records we have noticed that you have not attended the last two annual

meetings. Since a third absence would constitute a violation of College policy, I wanted

to send this reminder to you. If you miss another meeting during your 7-year tenure, your

associate membership status will be referred to Council. Council is empowered to

determine final action to be taken in cases where an Associate Member has more than

two absences during their tenure.

The College is honored to have you as an Associate Member, and we hope that College

membership and attendance at the Annual Meeting remains an important part of your

professional and scientific activities.

Sincerely,

Alan Frazer, Ph.D.

ACNP Secretary

Xc: Ronnie Wilkins, Executive Director

March 26, 2013

Richard Bergeron, M.D., Ph.D.

Ottawa Health Research Institute

725 Parkdale

Psychiatry

Ottawa, ON K1Y 1K7

CANADA

RE: Notice of Associate Membership Termination

Dear Dr. Bergeron:

Associate membership in the ACNP is based, in part, on an assumption that the

Associate Member will be active in the College and will regularly attend the annual

meetings. In fact, the ACNP By-laws state that Associate Members may miss no

more than two meetings during their 7-year tenure unless excused by Council.

In a letter dated March 26, 2012, we advised you of the ACNP Associate Member

attendance policy. In a review our records we note that you have not attended the last

three annual meetings. It is therefore necessary to terminate your associate

membership in the College.

Sincerely,

Ronnie D. Wilkins, Ed.D., CAE

Executive Director

University of Ottawa, 451 Smyth Rd, RM 3501, Ottawa, ON K1H 8M5

Richard Bergeron, MD, PhD, FRCPC Assistant Professor Department of Psychiatry & Department of Cellular & Molecular Medicine University of Ottawa Senior Scientist Neurosciences Ottawa Hospital Research Institute

Tel: 613 729 2068 Fax: 613 729 1226 Email:

[email protected]

http://www.ohri.ca/profiles/bergeron.asp

May 31, 2013

To Whom It May Concern: RE: Continued Associate Membership of Dr. Richard Bergeron to ACNP I am writing to request continued membership to the ACNP. I have been unable to attend the meetings for the last 4 years due to my commitment as a Grant Reviewer for the Canadian Institutes of Health Research. I was on the Neuroscience Panel and the meetings were always scheduled in early December, thus conflicting with the ACNP meetings. It is my intention to continue to attend these excellent scientific meetings and I do not want my membership to laps. If there are any penalties to pay, please send me the invoice so that I may continue my membership. I am very willing to confirm my leave by asking the chair of the Neuroscience Panel to write a confirmation letter for my participation as a reviewer for CIHR for the last 4 years. I am looking forward to attending the next ACNP meeting and would certainly provide whatever is required in order to continue my membership. Sincerely,

Richard Bergeron, MD, PhD, FRCPC Ottawa Hospital Research Institute

[email protected]

Henry A. Nasrallah, M.D. Professor of Psychiatry and Neuroscience Vice Chair for Education and Training

Department of Psychiatry and Behavioral Neuroscience University of Cincinnati College of Medicine

Office: 513-558-4615 Fax: 513-558-4616 Email: [email protected]

260 Stetson Street Suite 3200

Cincinnati, OH 45219

February 11, 2013 American College of Neuropsychopharmacology 5034-A Thoroughbred Lane Brentwood, TN 37027 Re: Nasrallah Endowment To the ACNP Council and Executive Director Wilkins, On December 28, 2012, my wife Amelia and I made a gift of 1000 shares of PSX stock to the ACNP, valued at approximately $54,000 (which is currently valued at about $64,000). It is our intent that this endowment be used to fund an award for excellence in basic, clinical or translational research in schizophrenia and other psychotic disorders. The College has our consent to use both the principle and earnings to fund this award. We suggest the award to be $2000 plus $1000 towards travel expenses for a total of $3000 annually for the first 5 years, following which it can be increased by 10% for the following 5 years. Council will determine the amounts after 10 years. We understand that the ACNP Council will discuss with us the specific name of the award and that the following options are being considered:

1. The Henry and Amelia Nasrallah “Rising Star” Research Award for psychosis research (which is our first choice)

2. The Henry and Amelia Nasrallah “Young Investigator” Research Award in serious neuropsychiatric disorders (young is stipulated to be 40 and under at the time of being selected)

We would like this award to be presented annually. We also prefer that the award be verbally announced for the first time during the awards ceremonies of the 2013 ACNP Annual Meeting and at the business meeting of that same meeting so that it is included in the minutes. The first recipient of the award should be given this award at the 2014 ACNP Annual Meeting, which happens to be the 30th anniversary of Henry’s election into the ACNP {Dec 1984]. We also request that Henry be an ex-officio, non-voting member of the Selection Award. Thank you and we are delighted to support the vital scientific mission of the ACNP. We will consider adding to this endowed fund in the future. Sincerely, Henry and Amelia Nasrallah

Henry A. Nasrallah, M.D. Professor of Psychiatry and Neuroscience Vice Chair for Education and Training Director, Schizophrenia Research Program Editor-In-Chief, Schizophrenia research

Ronnie, Thanks for the response. Let us think deliberate about the possibility of adding to the gift until the $100,000 threshold is reached. No rush to establish the award right now. Will make the decision to the latter part of this year, factoring in the value of the stock at that time [some projections say it might reach $75,000 by then] BTW: We NEVER ask for a gift to be returned ! It’s not in our value system… Thank you. Henry From: Ronnie Wilkins [mailto:[email protected]] Sent: Tuesday, February 26, 2013 5:36 PM

To: Nasrallah, Henry (nasralha) Subject: RE: ACNP endowed award

Dear Henry, I was able to bring your email to the attention of Council on the Executive Committee call today. While everyone recognizes that you have made a very generous gift to ACNP, nonetheless Council believes that there would have to be a much higher threshold before we could name an award after a member. As I said earlier, the fact that we require a $100,000 minimum for a named travel award is a benchmark that Council believes we have to recognize as relevant. However, Council offered to proceed with naming the award either the Young Investigator Research Award for Serious and Persistent Mental Illness, or the Young Investigator Award for Psychosis Research, and in the application, in descriptions of the award, and in materials promoting the award that we would include an acknowledgement that the award has been made possible by “a generous gift from Henry and Amelia Nasrallah”. The award recipient would be selected by the awards committee according to their usual process of accepting and evaluating applications for all ACNP awards. Council does not think it would be appropriate for you to become an ex officio member of that committee. I hope that you will find this an acceptable alternative. If not, we understand that you have the right to request that your gift be returned and we would, of course, honor that request. Best regards, Ronnie From: Nasrallah, Henry (nasralha) [mailto:[email protected]] Sent: Monday, February 25, 2013 5:50 PM

To: Ronnie Wilkins Subject: RE: ACNP endowed award

Dear Ronnie, I was not aware of the policy re a name award. My wife Amelia, who co-owns our assets, agreed to the donation with the understanding it would establish a name award [thus: Henry and Amelia Nasrallah

mailto:[email protected]


Award]. I also conceived of it as an award for research excellence, not a travel award, but obviously the awardee would have to travel to the ACNP meeting to attend and receive the award. A gift of $100,000 would use only the proceeds and thus will remain in perpetuity. On the other hand, you and I discussed using the proceeds as well as some of the principle for this award, which would make it last 30-40 years perhaps before the funds are depleted. So can you take that into account and make an exception given our intent and lack of knowledge about the recent policy change by Council? Is so, we accept that the award be called “ The Henry and Amelia Rising Star Award for Psychosis Research”. As you know, Amelia has served as the Sr. Managing editor for the journal Schizophrenia Research for the past quarter century since I founded it in 1988, and is a faculty member at UC and the Director of Clinical Research Management for the department of Psychiatry and Behavioral Neuroscience. Thus, we both share a strong passion for research excellence in psychotic disorders. Thank you.

Henry A. Nasrallah, M.D. Professor of Psychiatry & Neuroscience Vice Chair/Education and Training Director, Schizophrenia Program University of Cincinnati College of Medicine 260 Stetson Street, Suite 3200 Cincinnati, OH 45219 Phone: 513-558-4615 Fax: 513-558-4616 Email: [email protected] Editor-In-Chief: Schizophrenia Research

Editor-In-Chief: Current Psychiatry

From: Ronnie Wilkins [mailto:[email protected]]

Sent: Saturday, February 16, 2013 8:16 PM To: Nasrallah, Henry (nasralha)

Cc: Ronnie Wilkins

Subject: FW: ACNP endowed award

Dear Henry, Thank you for this letter and for the permission to use both principle and interest in making the awards over the years. This gift should provide funds to recognize excellent research in severe psychosis for many years. As Council discussed your generous gift and how the College could use it, the names for the award that were to be considered were either Young Investigator Research Award for Serious and Persistent Mental Illness, or Young Investigator Award for Psychosis Research. Council was not aware that you wanted your name included in the name of the award. A few years ago Council made a policy that a named travel award would require a gift of $100,000. This policy was set in response to requests from members to establish an award in honor of a particular member. Although this would not be a travel award, Council did refer to that policy as a guideline that should be considered as most relevant in this

instance as well. Would you be willing to accept the name as the Rising Star Research Award for Psychosis Research? If that is a problem, please let me know.



Best regards, Ronnie From: Nasrallah, Henry (nasralha) [mailto:[email protected]]

Sent: Monday, February 11, 2013 6:17 AM

To: Ronnie Wilkins Subject: RE: ACNP endowed award

Sorry, Ron, forgot to attach the letter the first time. Here it is Henry

From: Nasrallah, Henry (nasralha)

Sent: Monday, February 11, 2013 7:16 AM To: 'Ronnie Wilkins'

Subject: RE: ACNP endowed award

Hello Ronnie, Attached is the letter re the gift. Thank you Henry

Henry A. Nasrallah, M.D. Professor of Psychiatry & Neuroscience Vice Chair/Education and Training Director, Schizophrenia Program University of Cincinnati College of Medicine 260 Stetson Street, Suite 3200 Cincinnati, OH 45219 Phone: 513-558-4615 Fax: 513-558-4616 Email: [email protected] Editor-In-Chief: Schizophrenia Research

Editor-In-Chief: Current Psychiatry

From: Ronnie Wilkins [mailto:[email protected]]

Sent: Friday, February 08, 2013 8:56 AM

To: Nasrallah, Henry (nasralha) Subject: RE: ACNP endowed award

Okay. No problem. Thanks. From: Nasrallah, Henry (nasralha) [mailto:[email protected]]

Sent: Friday, February 08, 2013 6:50 AM

To: Ronnie Wilkins Subject: ACNP endowed award





Hello Ronnie, I went on a family vacation since we spoke and have been very busy after my return [as usual: things pile up]. Also, I thought there was no rush as we discussed because I wanted the award to start in 2014 [after being announced in late 2013]. I promise to send you the final letter wording soon. Best, Henry From: Ronnie Wilkins [mailto:[email protected]]

Sent: Thursday, February 07, 2013 8:52 AM To: Nasrallah, Henry (nasralha)

Subject: FW: Your gift to ACNP

Hi Henry, Have you had a chance to draft the letter I mentioned in the below email? Are there any questions I need to answer? Thanks, Ronnie From: Ronnie Wilkins

Sent: Wednesday, January 16, 2013 2:44 PM

To: 'Nasrallah, Henry (nasralha)' Subject: Your gift to ACNP

Dear Henry, As we discussed on the phone today, we would like to have a letter from you regarding the generous gift you made to the ACNP. In order that we are sure that the gift is recorded properly on our books and that your wishes are followed we would like a letter from you with language as follows: Dear _________: On December 28, 2012 my wife, Amelia, and I made a gift of 1,000 shares of stock to the ACNP, valued at approximately $54,000. We want that gift to be used to fund an award for excellence in schizophrenia research. The College has our permission to use both the principal and the earnings from the principal to fund this award. We understand that the ACNP Council will discuss with us the specific name of the award, and that two options are being considered: 1) Young Investigator Research Award for Serious and Persistent Mental Illness, or 2) Young Investigator Award for Psychosis Research. We also understand that we will be informed as Council determines if the award should be presented annually or biennially. We would like for the award to be announced for the first time at the 2013 ACNP Annual Meeting and awarded for the first time at the 2014 Annual Meeting. Sincerely,


We will record your gift in the ACNP financial records as a restricted asset. It will then show up on our audited financial report as such, and each year the amount will be adjusted to reflect earnings from that year added to the principal amount and funds used for the award deducted. Thank you again for such a generous gift. Best regards, Ronnie

Ronnie D. Wilkins, Ed.D., CAE Executive Director American College of Neuropsychopharmacology 5034A Thoroughbred Lane Brentwood, TN 37027 Telephone (615) 324-2360 Fax (615) 523-1715 Cell (615) 390-7271 Email [email protected] www.acnp.org


http://www.acnp.org/

http://www.facebook.com/pages/American-College-of-Neuropsychopharmacology/150012255079741

http://twitter.com/acnporg

MEMORANDUM

To: File

From: Ronnie Wilkins

Date: June 14, 2013

Re: Instructions for annual calculation regarding the Nasrallah gift

1. On December 31, 2012 the value of the gift of stock donated to the ACNP was $50,570.

2. The stock was sold in May, 2013 and the proceeds re-invested in the ACNP’s investment account

managed by SunTrust Investments.

3. On December 31, 2013 we should look at the total rate of return on the SunTrust account, and

assume the Nasrallah gift grew by the same percentage as the overall account.

4. Using the rate of return from step 3, add to the initial principal the amount gained during 2013.

5. Subtract the amount of money used to fund the award in 2013 from the sum in step 4.

6. The resulting amount becomes the new base.

7. Repeat steps 3 – 6 each year.

The group may be small but we need to devote sometime next week to this issue. Thanks -----Original Message----- From: Lewis, David Sent: Thursday, June 13, 2013 11:25 AM To: 'Kalivas PhD, Peter W'; Insel, Thomas (NIH/NIMH) [E]; Krystal, John; Eric Nestler Subject: RE: NATIONAL CONFERENCE ON MENTAL HEALTH AT THE WHITE HOUSE Thanks, Tom. Enlightening if discouraging. Peter, I agree that we should discuss the issue at Council next week; it seems we may need a sustained response to address the shift in messages. Our strategy group for PA met yesterday. We will be seeking linkages with the advocacy groups who have influence to convey the message that "current treatments can help today, but we must do better tomorrow." -----Original Message----- From: Kalivas PhD, Peter W [mailto:[email protected]] Sent: Saturday, June 08, 2013 10:23 AM To: Insel, Thomas (NIH/NIMH) [E]; Lewis, David; Krystal, John; Eric Nestler Subject: Re: NATIONAL CONFERENCE ON MENTAL HEALTH AT THE WHITE HOUSE Whether we respond or not is up to you as president David. Your insight below on the evolution behind the focus/wording of the recent initiatives is educational, and seems accurate. Perhaps at summer council we can discuss whether a statement would be useful that keeps a national focus on the importance of supporting a biologically-based 'cure' for neuropsychiatric diseases . As Tom has framed it below, a formal statement could largely be one of being included in the BRAIN initiative along with other neurological diseases, and not to beat up directly on the other recent initiatives. If this appears competitive with our neurological disease research counterparts, so be it. Given the trends in thinking about brain disorders brought out by this email exchange, it would seem that we still need to remind our colleagues, and society at large, that behavioral disorders deserve the same recognition (and new funding) being associated with researching other biologically based diseases. If we go fwd along this vein, I rescind my earlier thought about SFN, they would be a good ally in a statement of this kind as they are a society inclusive of all brain disorders. Peter On 6/7/13 8:59 AM, "Insel, Thomas (NIH/NIMH) [E]" <[email protected]> wrote: >Have been following this conversation with interest. Let me add two



>observations: >!. April 2nd WH conference on BRAIN initiative identifies the need for >better brain tools to Alzheimers, Parkinsons, autism -- no mention of >schizophrenia, bipolar, PTSD. June 3rd WH conference on mental health >identifies the problem as stigma -- no mention of the brain, need for >better diagnostics or therapeutics, or even the April 2nd WH conference. >2. Worth reading this op-ed from Pete Earley in USA Today. ("Obama >deserves praise for focus on mental health, but failed to invite the >right experts ><http://www.usatoday.com/story/opinion/2013/06/04/pete-earley-on-obama- >and >- >mental-health/2389313/>," June 4). > > > >Thomas R. Insel, MD >Director, NIMH/NIH/DHHS >Bethesda, MD 20892 >301-443-3673 (ph) > > > > > > >On 6/7/13 8:35 AM, "Lewis, David" <[email protected]> wrote: > >>I fully agree with the intent expressed below, but have some concerns >>about how the message is delivered. >> >>I have been involved with the PA state legislature over the past months. >>At the risk of creating caricatures, I would suggest the discussions >>have been as follows: One camp has argued that mentally ill >>individuals are prone to violence, should be listed in a national >>registry, and appropriately monitored (or incarcerated). (Our county >>DA recently called a press conference to argue that county funds which >>support a highly successful 24x7x365 crisis center would be better >>spent on increasing space for the mentally ill in the county jail!) >>The other camp has delivered the Obama message: effective treatments >>are available, treatment reduces the risk of violence, and so reducing >>stigma and engaging and maintaining individuals in treatment should be the goal. >>Both camps appeal to the public goal of QUICKLY making our society safer. >> >>Brain research to improve our understanding of mental illness tends to >>be regarded as irrelevant by the first camp and as competing for >>resources by the second camp. All agree that neuroscience research >>cannot guarantee an effective deliverable by a date certain that will


>>achieve the goal of making society safer. My interpretation is that >>this conundrum contributed to the WH creating separate platforms for >>1) addressing mental health issues by endorsing the "camp 2" position, >>and 2) focusing on brain research as a means of economic growth and >>advancing care for wounded warriors and those with brain diseases not >>typically linked to violence. >> >>So, given this perspective, I am concerned that having ACNP take issue >>with Obama's message because it left out research could be >>counter-productive. I am happy to hear correctives to this perspective >>or ideas about how we could promote making the brain mapping >>initiative better funded and more immediately relevant to mental health research. >> >>Thanks >> >> >> >>-----Original Message----- >>From: Kalivas PhD, Peter W [mailto:[email protected]] >>Sent: Thursday, June 06, 2013 9:32 AM >>To: Krystal, John; Insel, Thomas (NIH/NIMH) [E]; Lewis, David; Eric >>Nestler >>Subject: Re: NATIONAL CONFERENCE ON MENTAL HEALTH AT THE WHITE HOUSE >> >>Makes sense to me John, lets see what David wants to do, happy to help >>write (sans moons of Saturn), we can then send a draft to SFN. >>Although it occurs to me that SFN has an obvious bias for fundamental >>biological over treatment research, so a message from us as a largely >>Psychiatric organization may have more influence. >> >>On 6/6/13 9:22 AM, "Krystal, John" <[email protected]> wrote: >> >>>My point, though, is that perhaps the ACNP should weigh in on this >>>issue. >>>Perhaps sending a letter to the editor to NYT or WSJ responding to >>>the positive aspects of the message, but highlighting its gap. In >>>this way, ACNP is different than the APA, which endorsed the message >>>without highlighting its failure to endorse research as a path >>>forward to addressing the efficacy gap. Perhaps SFN would partner >>>with ACNP in a letter. >>> >>>JK >>> >>> >>>On 6/6/13 9:16 AM, "Kalivas PhD, Peter W" <[email protected]> wrote: >>> >>>>Hi Tom >>>>As I understanding it, your primary message is to refine diagnosis




>>>>in order to better refine treatments for neuropsychiatric diseases. >>>>To accomplish this, the VPs message is the most accurate, we don't >>>>know enough about the brain yet, and only by understanding the >>>>fundamental workings of the brain can we translate cognitive and >>>>behavioral disorders into neurobiological diseases with >>>>neurobiological rationales for treatment and cure. >>>> >>>>This is not say that sociological interventions with imperfect >>>>understanding of what they are doing biologically should not be >>>>utilized to their best advantage, often to great benefit individually. >>>>Improving our sociological treatment infrastructure is certainly >>>>critical and politically very tangible. >>>> >>>>However, thinking we can cure these diseases with our current >>>>understanding of the brain is akin to thinking we can colonize the >>>>moons of Saturn using our current Apollo-era technology. >>>>Peter >>>> >>>>On 6/6/13 6:15 AM, "Insel, Thomas (NIH/NIMH) [E]" >>>><[email protected]> >>>>wrote: >>>> >>>>>Meant to include : >>>>>http://www.nimh.nih.gov/about/director/index.shtml#p145467 >>>>> >>>>>Thomas R. Insel, MD >>>>>Director, NIMH/NIH/DHHS >>>>>Bethesda, MD 20892 >>>>>301-443-3673 (ph) >>>>> >>>>> >>>>>From: <Krystal>, "Krystal, John" >>>>><[email protected]<mailto:[email protected]>> >>>>>Date: Wednesday, June 5, 2013 10:40 PM >>>>>To: David Lewis <[email protected]<mailto:[email protected]>>, Eric >>>>>Nestler <[email protected]<mailto:[email protected]>>, >>>>>"[email protected]<mailto:[email protected]>" >>>>><[email protected]<mailto:[email protected]>> >>>>>Cc: "Insel, Thomas (NIH/NIMH) [E]" >>>>><[email protected]<mailto:[email protected]>> >>>>>Subject: FW: NATIONAL CONFERENCE ON MENTAL HEALTH AT THE WHITE >>>>>HOUSE >>>>> >>>>>I still don't see anything here about research on mental illness >>>>>causes and treatments. In this way, the message is disappointing. >>>>> >>>>>JK >>>>>


http://www.nimh.nih.gov/about/director/index.shtml#p145467

mailto:[email protected]%3cmailto:[email protected]



mailto:[email protected]%3cmailto:[email protected]%3e



>>>>>From: < >, Tanya >>>>><[email protected]<mailto:[email protected]>> >>>>>Date: Wednesday, June 5, 2013 10:30 PM >>>>>Subject: NATIONAL CONFERENCE ON MENTAL HEALTH AT THE WHITE HOUSE >>>>> >>>>> >>>>> >>>>>Good evening, >>>>> >>>>>We wanted provide you information on the National Conference on >>>>>Mental Health. Please share with your organizations and members. >>>>> >>>>> >>>>> >>>>>[cid:[email protected]] >>>>> >>>>> >>>>> >>>>>On Monday, June 3rd, President Obama and Vice President Biden >>>>>hosted a National Conference on Mental Health at the White House as >>>>>part of the Administration¹s effort to launch a national >>>>>conversation to increase understanding and awareness about mental >>>>>health. The conference brought together people from across the >>>>>country, including mental health advocates, educators, health care >>>>>providers, faith leaders, members of Congress, representatives from >>>>>local governments and individuals who have struggled with mental >>>>>health problems, to discuss how we can all work together to reduce >>>>>stigma and help the millions of Americans struggling with mental >>>>>health problems recognize the importance of reaching out for assistance. >>>>> >>>>>Building on Progress >>>>> >>>>>The conference builds on the President¹s plan to reduce gun >>>>>violence, which calls on Health and Human Services Secretary >>>>>Kathleen Sebelius and Education Secretary Arne Duncan launched a >>>>>national conversation to increase understanding and awareness of >>>>>mental health. It also builds on a number of steps to raise >>>>>awareness and improve care for those experiencing mental health >>>>>issues, including veterans, a topic Veterans Affairs Secretary Eric >>>>>Shinseki addressed in the closing session. For >>>>>example: >>>>> >>>>> >>>>>· Expanding Mental Health Coverage. The Affordable Care Act >>>>>will >>>>>expand mental health and substance use disorder benefits and parity >>>>>protections for 62 million Americans. In addition, thanks to the >>>>>health care law, beginning in 2014, insurers will no longer be able


cid:[email protected]

>>>>>to deny anyone coverage because of a pre-existing mental health >>>>>condition. The law already ensures that new health plans cover >>>>>recommended preventive benefits without cost sharing, including >>>>>depression screening for adults and adolescents and behavioral >>>>>assessments for children. >>>>> >>>>> >>>>>· Supporting Young People. The President¹s Fiscal Year 2014 >>>>>Budget includes a new $130 million initiative to help teachers and >>>>>other adults recognize signs of mental illness in students and >>>>>refer them to help if needed, support innovative state-based >>>>>programs to improve mental health outcomes for young people ages >>>>>16-to-25, and help train 5,000 additional mental health >>>>>professionals with a focus on serving students and young adults. >>>>> >>>>> >>>>> >>>>>· Improving Access to Services for Veterans. In response to >>>>>the >>>>>President¹s Executive Order in August of 2012, the Department of >>>>>Veterans Affairs has achieved their goal of increasing capacity >>>>>by hiring 1,600 new mental health providers, over 300 peer-to-peer >>>>>veteran specialists, establishing 24 pilot projects in nine states >>>>>where VA is partnering with community mental health providers to >>>>>help Veterans access mental health services in a timely way and >>>>>enhancing the capacity of its Crisis Line by >>>>>50 percent. >>>>> >>>>> >>>>> >>>>>o At the conference, the President announced that the Department of >>>>>Veterans Affairs is directing 152 of its health care centers >>>>>nationwide to conduct Mental Health Summits with community >>>>>partners, including local government officials, community-based >>>>>organizations, and Veteran Service Organizations starting July 1 >>>>>through September 15. The Summits will identify and link >>>>>community-based resources to support the mental health needs of >>>>>Veterans and their families, as well as help increase awareness of >>>>>available VA programs and services. >>>>> >>>>> >>>>>o Also at the conference, White House staff members from the >>>>>Domestic >>>>>Policy Council, the Office of Public Engagement, Joining Forces, >>>>>and Dr. >>>>>Biden¹s Office met with representatives from a number of >>>>>organizations focusing on military family members during a >>>>>break-out session to address family issues impacting access to mental health.

>>>>>The dialogue focused on ways to improve mental health and >>>>>well-being for the Veterans and their families in their local communities. >>>>>For additional information please see >>>>>https://twitter.com/JoiningForces/status/342411705046933504 >>>>> >>>> >>> >> >

https://twitter.com/JoiningForces/status/342411705046933504

2013 Committee Charges

Audit Committee

The duties of the committee include.

CHARGE: Selection of and communication with the independent auditors.

UPDATE: Frasier, Dean & Howard completed the FY13 audit. Committee will

review proposals prior to FY14 audit, if deemed necessary.

CHARGE: Review and approval of annual audited financial statements.

UPDATE: The committee received the completed FY13 audit on June 17 and is

in the process of reviewing the report. A call will be scheduled for July or

August.

CHARGE: Discussion of internal control matters with the independent auditors.

UPDATE: The committee will discuss as necessary on the July/August

conference call.

CHARGE: Accessible to be contacted, and respond to any reported instances of

fraud or unethical financial behavior.

UPDATE: No instances of fraud or unethical financial behavior have been

reported.

CHARGE: Conduct a periodic analysis of ACNP financial statements.

UPDATE: The committee will review as needed.

CHARGE: Periodically review accounting policies and procedures.

UPDATE: The committee will review as needed.

CHARGE: Discuss and present recommendations to Council regarding matters

arising from the Committee’s review of policies and procedures, and those

matters arising from the audit.

UPDATE: The committee will present report to Council after it has completed its

review of the FY13 audit.

CHARGE: The Committee should review their duties yearly and review and

approved the audited financial statements.

UPDATE: Will review as needed. Will approve the audited financial statements

in July or August.

Education & Training Committee

CHARGE: Continue the pre-doctoral travel award. The committee should liaise with

other groups such as NIH who are developing their own pre-doctoral programs.

UPDATE: A sub-committee was formed to promote the MD & MD/PhD trainee travel

award and increase the number of applicants for the 5 available student slots. The name

of the student trainee award was changed from Pre-doctoral Trainee to MD & MD/PhD

Trainee to avoid eligibility confusion. The group targeted and communicated with

MD/PhD program directors identified by Medical Scientist Training Program (MSTP)

site. Nancy Desmond, NIH Office of Research Training and Career Development, was

contacted.

CHARGE: Facilitate the 2012 TA Survey and make improvements to the program based

on feedback.

UPDATE: Of the 62 ACNP and ADAA travel awardees surveyed, 31 completed surveys

were returned for a 50% response rate. Overall, awardee satisfaction with the meeting is

high, however, mentor matching should be improved and selection of a luncheon speaker

will be refined to choose a speaker more closely relatable to the awardees current career

status. The committee would like to increase response rate by distributing a paper survey

during the Travel Awardee luncheon.

CHARGE: Work with the Membership Advisory Task Force to develop a program to

keep past travel awardees involved in the College and the meeting and assist them in

pursuing Associate membership.

UPDATE: The committee discussed financial limitations that may be keeping PTAs

from attending their allotted 4 subsequent meetings and thus dropping off from active

participation in the College. Past travel awardees do receive discounted registration fees

but no other travel support. The group suggested engaging PTAs in the annual meeting

program (panels, mini-panels and study groups) by providing a list of PTAs along with

their areas of research to the College membership and asking them to consider inviting a

young awardee, where appropriate, to participate on their proposed session. This would

have two-fold benefit; 1) the PTA would be eligible for financial support as a non-

member participant (non-members are only eligible for financial support every other year

as defined by ACNP policy) and, 2) the session may receive extra consideration for

including a PTA/early career researcher as determined by the Program Committee. The

committee would recommends including this strategy for the 2014 meeting.

CHARGE: Coordinate the 2013 Travel Award program, which includes:

1. Implement the new policy that applicants must be 8 years from their last

training. Scoring applicants using the new, revised scoring system.

UPDATE: implemented

2. Selecting speakers for the Travel Awardee events at the Annual

Meeting.

UDATE: The committee will rotate speaker by male/female,

basic/clinical speakers on alternating years and will avoid inviting

speakers who have previously presented at TA functions. Additionally,

the group would like to consider scheduling two shorter presentations,

one speaker who may be a closer contemporary to the awardees and a

second more advanced in their career.

3. Working with David Sibley and the website subcommittee to announce

and publicize the TA program and awardees on Facebook and Twitter,

as a way to be more accessible to a younger scientific audience.

UPDATE: no action

4. Continue with the Travel Awardee Poster Session.

UPDATE: The poster reception, new in 2012, was well received but

needs more formal structure. Awardees will be given better instructions

regarding expectations and will be assigned times to present/attend their

poster. The committee is considering inviting ACNP Associate

Members to the poster reception to more closely align the awardees with

members who have recent membership advice

CHARGE: Review and revise the travel awardee and mentor matching process selection.

UPDATE: The committee will implement a new system for matching awardees to

mentors like one that is used at Society for Neuroscience (SFN) where the awardee would

be provided a list of mentors along with their areas of interest and the awardee would

indicate their top 4 choices of mentors. In addition, the committee would like mentors to

receive a list of important College related informational policies regarding attaining

membership so that they will be prepared to answer questions from their awardees. The

informational policies will be developed in coordination with the Membership Committee

and provided to 2013 travel awardee mentors.

CHARGE: Consider whether past travel awardees who attend the meeting should be

invited to travel awardee functions.

UPDATE: No action.

Ethics Committee

CHARGE: Deal with any Ethics issues that may be brought before the committee.

UPDATE: No issues have been brought to the committee to date.

CHARGE: Consider submitting a study group or panel session on an ethics-related issue

to the 2013 call for submissions.

UPDATE: The session, “Mental illness, violence and the gun control debate: evidence,

policy, privacy and stigma, was developed and submitted as a Study Group for Program

Committee consideration.

CHARGE: Review the ACNP Disclosure Policy and determine if there is a need for an

update. Consider using the standard NIH policy being developed.

UPDATE: The committee reviewed the policy and did not think there was a need for any

changes.

Honorific Awards Committee

CHARGE: In light of the data regarding women members who have received honorific

awards, Council would like the Awards Committee to strive to increase the number of

women awardees in the coming years.

UPDATE: The committee has received the following nominations for review:

2 Efron, 2 Elkes, 2 Killam (1 woman), 6 Axelrod (1 woman) and 1 Media Award

Liaison Committee

CHARGE: Continue to support the ACNP Advocacy Affiliates in their endeavors and

look for confluence of interest. Update them on the efforts of other organizations and

initiatives to increase the development of new treatments in the field.

UPDATE: The committee continues to engage affiliates on conference calls and will

encourage them to again present a poster at the meeting. Additionally, affiliates have

been encouraged to let the committee know when their events, meetings, etc. are taking

place so the committee can identify a local ACNP member who may attend be able to

attend/participate in the function.

CHARGE: Review the ACNP Code of Conduct for Participating Organizations. Is the

document in need of an update? Should we require organizations to abide by the

registering all trials on ClincialTrials.gov now that this is required by law? Language

should be added to communicate that it is only industry activities that relate directly to

ACNP that should fall under this purview.

UPDATE: The committee is working on recommended changes for Council review.

CHARGE: Stay in contact with Nancy Ator, the ACNP representative for AAALAC.

Obtain a yearly update. Continue to monitor the revisions of the Guide for Care and Use

of Laboratory Animals.

UPDATE: Nancy Ator continues to participate on committee calls and give updates

regarding revisions to the guide for Care and Use of Laboratory Animals.

CHARGE: Work with the website editors to add content on the site regarding NIH

initiatives and our Advocacy Affiliate initiatives.

UPDATE: No action at this time.

CHARGE: Continue to work on the CTSA initiative so that College members can

advocate for securing more of the funding for CTSA’s towards CNS.

UPDATE: Co-chair Markus Heilig continues to update the committee on NCATS/CTSA.

The committee would like to include NCATS Director, Chris Austin in the NIH Institutes

Director’s sessions during the Annual Meeting.

Membership Committee

CHARGE: Evaluate nominations and make recommendations for Associate Members,

Members and Fellows.


CHARGE: Council would like the Membership Committee to continue to increase the

number of women and under-represented minority Associate and Regular Members in the

coming years.


Program Committee

CHARGE: Consult with the President to select ad-hoc members for the committee should

there be a need for more expertise.

UPDATE: Ad-hoc members Joseph Callicott, David Grandy, Robert Greene, James

Sutcliffe, and Jeremy Veenstra-VanderWeele were added to compensate for members

who cannot attend the summer meeting and to fill gaps in expertise.

CHARGE: Council would like the Program Committee to continue to pay special

attention and continue to increase the number of women and under-represented minorities

on the program at the Annual Meeting in the coming years.

UPDATE: During the abstract submission process, data was collected for participant age,

gender, and ethnicity. This information was available during review process as well as

the Program Committee summer meeting in the form of charts and graphs.

CHARGE: Consider shortening the hot topics session so that the one session is not so

long, and adding a mid-session break.

UPDATE: Two, fifteen minute breaks will be scheduled during this session.

CHARGE: The Program Committee should investigate how to incorporate ARS

(audience response system) into programming for 2013. This may be used for a more

interactive Institute Directors’ Session.

UPDATE: This will be discussed at the summer meeting.

CHARGE: Continue to look for more clinical science to bring into the program.

UPDATE: This will be discussed at the summer meeting.

Public Information Committee

CHARGE: Continue to work with Dave Sibley, ACNP Website Editor, and the Education

and Training Committee to develop content for the ACNP website and the pages for

Public & Media Resources.

UPDATE: Paul Kenny and Ira Glick are working with website editor, David Sibley, to

review educational content for the website. Additionally, Associate Website Editor,

Garret Stuber is participating on committee calls as a resource for website issues.

CHARGE: Continue screening articles in Neuropsychopharmacology that should be

released to the media and forward those to the Nature Press Office.

UPDATE: Four releases have been completed to date. They are:

Using marijuana in pill form to alleviate pain

A taste for alcohol

Visual brain circuit linked to antidepressants

Marijuana may increase nicotine dependence in rats

CHARGE: Review accepted abstracts and hot topics for the 2013 Annual Meeting from

the Program Committee for release to the media. Releases in 2013 will need to be

written by committee members.


CHARGE: Nominate a person for the 2013 Media Award.

UPDATE: Charlie Rose has been nominated by the committee for the 2013 Media

Award.

CHARGE: Consider adding a person from the press as an Ad Hoc member to the

committee.

UPDATE: The committee has agreed to add Maia Salavitz as an ad hoc member for

2013. Ms. Salavitz has spoken with Dr. Kenny and has agreed to this position. A formal

invitation will be extened.

Publications Committee CHARGE: Continue to support and monitor the progress of Neuropsychopharmacology

Reviews.

UPDATE: NPPR 2014 is progressing nicely, and we are planning for 2015.

CHARGE: Continue to support the Public Information Committee by alerting them to

Neuropsychopharmacology papers accepted and screened for potential media release by

Editor-in-Chief, Bill Carlezon.

UPDATE: When articles are identified as press worthy, Dr. Carlezon invites a PIC

member to draft a release that is reviewed by the Public Information Committee.

CHARGE: Continue to monitor the progress of the ACNP website and support Dave

Sibley, the ACNP Website Editor, to ensure that the website provides the information and

functionality desired by members and provides appropriate and helpful information to the

general public.

UPDATE: The Managing Editor has worked with the ACNP website staff to ensure that

the information is updated as needed.

CHARGE: Review an award proposal for “best paper” in Neuropsychopharmacology

from Bill Carlezon.

UPDATE: The committee has invited the Associate and Deputy Editors to nominate

papers for this award and will be selecting a paper in the next couple months. In

addition, we are considering a best reviewer award.

TASK FORCES

Member Advisory Task Force – Sarah Timm

CHARGE: Develop a program with the Education and Training Committee to engage

past travel awardees in the College and the meeting.

UPDATE: The task force sent a letter earlier this year past travel awardees offering the

opportunity to get a new member mentor or to continue their relationship with their

original mentor. Those travel awardees who did not have an engaged mentor could

request to get another member. We received positive comments back from past travel

awardees about their mentors, and no one requested a new/additional mentor.

CHARGE: Conduct a survey to evaluate how the changes made over the past year have

impacted the Associate Members perception of the College.

UPDATE: A survey has been developed for Associate Members, Past Travel Awardees

and non-members who have attended the last three meetings. The survey will launch the

last week in June.

CHARGE: Continue the Associate Member reception for the 2013 class of Associate

Members at the 2013 Annual Meeting. Consider making this a poster reception like the

Travel Awardee Poster Reception.

UPDATE: The task force is planning another Associate Member reception at the 2013

Annual Meeting. They did consider adding posters to the reception, but agreed this

reception should be more informal and not include posters.

CHARGE: Present a poster at the 2013 Annual Meeting describing the progress the task

force has made in the current year.

UPDATE: In progress. This will be submitted in August.

CHARGE: Develop an FAQ document on questions that are asked by prospective new

members about the College. This should also include a recap of the policy changes and

their effect in the last year.

UPDATE: In progress.

CHARGE: Conduct a Career Development Session at the 2013 Annual Meeting.

UPDATE: The session titled, “Ask the Experts: Funding Strategies in the Current

Climate,” will be presented to the Program Committee in June for review.

Women’s Task Force

CHARGE: Select a speaker for the 2013 Women’s Luncheon.

UPDATE: In progress.

CHARGE: Continue to define ways to incorporate and advance young women in the

College.


Minority Task Force

CHARGE: Investigate how the College can successfully bring more minorities into the

College and the meeting.

UPDATE: The task force has completed one call and the Executive Office is gather

statistics regarding minority attendance and travel awards.

CHARGE: Develop statistics on past ACNP Minority Travel Awardees and do follow-up

to determine where they are in the field to date.

UPDATE: In process.

CHARGE: Work with NIDA regarding funding and promotion for Minority Travel

Awardees as offered by Nora Volkow.

UPDATE: In process.

AMERICAN COLLEGE OF

NEUROPSYCHOPHARMACOLOGY

Setting Direction for the College December, 2010

TABLE OF CONTENTS Core Ideology – Core Purpose and Core Values Page 2

Envisioned Future Page 3

Goals Page 4

Objectives Page 5

PREFACE

This document briefly describes the updated strategic plan for the ACNP. This plan is

intended to guide the ACNP leadership, including its Committees and Task Forces, in

translating the College’s core ideology, outlined below, into action. We recognize that

strategic plans are context-dependent. In this document, we articulate specific goals for

the ACNP that we anticipate will assist in guiding the college over the upcoming years.

We recognize that these goals will need to be updated regularly, perhaps every 3-5 years.

More frequently, the College will need to reevaluate the success of its strategies in

enabling the College to achieve its stated goals and introduce necessary amendments.

ACNP CORE IDEOLOGY

The Core Ideology consists of the Core Purpose – the ACNP’s reason for being – and

Core Values – enduring principles that guide the ACNP in all of its activities.

The Core Purpose and Core Values of the ACNP are described below.

ACNP Core Purpose

To contribute to alleviating human suffering by advancing the dissemination of

knowledge related to the biology of the brain as well as the biology, prevention, and

treatment of brain disorders; by promoting emergence of pioneering young scientists as

leaders within our College and within their fields of science; and by facilitating the

collaboration among relevant organizations and agencies.

ACNP Core Values

The ACNP strives for these Core Values:

Commitment to Excellence – ACNP members are committed to

excellence in the conduct of science, in the presentation of science at

ACNP meetings and in the ACNP journal, in the selection of the best

scientists as ACNP members, and in the mentorship of young scientists in

the field.

Commitment to Integrity – The ACNP and its members operate at the

highest level of integrity.

Commitment to Openness – ACNP members value the free exchange of

scientific information and open communication between membership and

leadership related to governance of the College.

Commitment to Clinical/Basic Exchange - ACNP members are committed

to providing a forum for the clinical/basic exchange of scientific

information, which is critical for the advancement and translation of

scientific discovery.

Commitment to Education and Training – ACNP members are committed

to training the next generation of neuropsychopharmacology researchers

and to disseminating research findings to scientific colleagues, mental

health professionals, and patients and patient representative groups.

Commitment to Collegiality – Membership in the ACNP indicates a desire

to participate in and to contribute to the College and its activities, as well

as a desire to collaborate with other members in the advancement of

science.

Commitment to Diversity – The ACNP is committed to diversity to foster

the involvement of women, under-represented minorities, and wide

geographical representation in the College and in

neuropsychopharmacology research, education, and treatment.

Commitment to Research Ethics – The ACNP membership is committed

to advancing humane and ethical research practices.

ACNP Mission Statement

The principal function of the College is to further research and education in

neuropsychopharmacology and related fields by: a) promoting the interaction of a broad

range of scientific disciplines of brain and behavior in order to advance the understanding

of causes, prevention and treatment of diseases of the nervous system including

psychiatric, neurological, behavioral and addictive disorders; b) encouraging scientists to

enter research careers in fields related to these disorders and their treatment; and c)

ensuring the dissemination of relevant scientific advances in these disorders.

ADOPTED BY COUNCIL

JULY 1997 (amended June 2010)

ACNP ENVISIONED FUTURE

This is a statement of what the ACNP wants to be, i.e. the Vision, and a vivid description

of the realized vision for the College.

Vision

To be the premier professional society for the exchange and dissemination of scientific

knowledge on the causes and treatments of disorders of the brain and behavior.

ACNP GOALS

Goals describe the outcomes the ACNP will achieve for its stakeholders, i.e. for the

members, patient advocacy groups, government research institutes, academia, industry,

and allied societies. These goals generally apply to a three- to five-year time frame, to be

reviewed and adjusted every year as appropriate.

GOAL 1: STANDARDS OF EXCELLENCE FOR COLLEGE MEMBERSHIP

The College will include the most respected scientists focused on disorders of the brain,

and these Members will present their cutting edge basic and clinical research at the

Meeting. They will also enhance the career development of young, talented investigators

informally and via the effective resource utilization.

GOAL 2: ANNUAL MEETING

The ACNP Annual Meeting will be consistently acknowledged as an exceptionally

stimulating forum that provides attendees with opportunities to deepen and broaden their

understanding of emerging research advances. It will also enhance the opportunities it

provides to young scientists to facilitate their emergence as future leaders of their

respective fields of research.

GOAL 3: ACNP PUBLICATIONS

Neuropsychopharmacology, Neuropsychopharmacology Reviews, the ACNP Website

and other ACNP Publications will continue to increase in national and international

standing among journals and electronic resources in psychiatry, neurology, neuroscience

and pharmacology.

GOAL 4: EFFECTIVE SOURCE OF SCIENTIFIC INFORMATION &

COLLABORATIVE RELATIONSHIPS

The College will be viewed as a valued resource for the dissemination of authoritative

knowledge of brain disorders and their treatment and will advance the scientific goals of

the College through collaborative relationships with patient advocacy organizations,

government, academia and industry.

ACNP OBJECTIVES

Objectives are the specific, measureable, desired outcomes associated with the

realization of its goals. They will be reviewed annually.

GOAL 1: STANDARDS OF EXCELLENCE FOR COLLEGE MEMBERSHIP

The College will include the most respected scientists focused on disorders of the brain,

and these members will present their cutting edge basic and clinical research at the

Annual Meeting. They will also enhance the career development of young, talented

investigators informally and via the effective resource utilization.

Objectives (to measure progress toward achieving the goal):

Increase diversity of College membership (including leadership) with respect

to involvement of women, under-represented minorities, and geographical

representation.

Increase associate member and member applications from younger scientists.

Facilitate the promotion of qualified members to fellows.

Attract members from all appropriate areas, including basic and clinical

research, emotional, cognitive and addiction research, neurological,

developmental and aging.

Possible Strategies: 1.1 Strengthen the outreach program for membership beyond those known by current

members.

1.2 Review, update and better communicate criteria for membership.

1.3 Consider ways to facilitate the transition from being a travel awardee to achieving

associate membership in the College.

1.4 Continue support for minority travel awardees, guests at annual meeting, etc. via

an outreach strategy and consider ways to better bridge such programs with

associate membership in the College.

1.5 Educate academic medical centers regarding the value of ACNP membership.

1.6 Increase the number of promising young investigators at the annual meeting by

expanding the number of invitations available for this purpose and by making

more creative, aggressive use of the associate member category.

1.7 Strengthen the role of associate members and promote their transition to full

membership by expanding their involvement in the annual meeting, in the

College’s committee work, etc.

1.8 Keep data and provide regular reports to Council regarding the progression of

travel awardees to associate membership and of associate membership to regular

membership.

GOAL 2: ANNUAL MEETING

The ACNP Annual Meeting will be consistently acknowledged as an exceptional

meeting that serves as a catalyst to expand the intellectual and technical aspects of

members’ research, training and treatment goals.


Maintain / increase high attendee satisfaction ratings of the meeting overall.

Maintain / increase high percentage of members who attend the meeting.

Maintain / increase high ratings of meeting by non-member attendees.

Maintain / increase attendees’ ranking of the meeting compared to other meetings.

Maintain / increase the quality of poster sessions as measured by attendee ratings.

Increase the breadth of topics presented at the Annual Meeting.

Possible Strategies (tactics to achieve the objectives):

2.1 Identify yearly the under-represented topic areas of the Annual Meeting and

communicate the need to the membership via RFP.

2.2 Actively encourage panel submissions in under-represented topic areas, though

acceptance will not be guaranteed.

2.3 Ensure the quality and diversity of programs by adding Ad Hoc Program

Committee Reviewers/Members when needed.

2.4 Increase discussion at the Annual Meeting by optimizing the role of discussants.

2.5 Enhance the role of Associate Members in the meeting to ensure younger

scientists are given opportunities to be more invested in the College.

2.6 Require panel submissions with redundant content from previous years to meet a

higher standard of quality, novelty, and importance to be accepted by the Program

Committee. The Program Committee may choose to ask several reviewers to

focus on reviewing for redundancy.

2.7 Continue encouraging members to bring more young people to the meeting and

publicize the invitation bank to the membership.

GOAL 3: ACNP PUBLICATIONS

Neuropsychopharmacology, Neuropsychopharmacology Reviews, the ACNP Website

and other ACNP Publications will continue to increase in national and international

standing among journals and electronic resources in psychiatry, neurology,

neuroscience and pharmacology.


Increased impact factor.

Increased number of manuscript submissions to the journal.

Increased number of submissions from leading investigators.

Increased number of submissions from ACNP members.

Increased selectivity (i.e. increased rejection rate)

Possible Strategies:

3.1 Ask the Journal editors and Publications Committee to consider changes in

journal policy to enhance impact factor, such as increase the number of

Commentaries, reduce the size of individual articles, and increase the number of

mini-reviews.

3.2 Neuropsychopharmacology Reviews, recently re-authorized for another three

years, should be reviewed in an ongoing manner to ensure its success and overall

benefit to Neuropsychopharmacology.

3.3 Improve the scope and reach of the ACNP Website and consider the

implementation of social network tools for the ACNP.

GOAL 4: EFFECTIVE SOURCE OF SCIENTIFIC INFORMATION AND

COLLABORATIVE RELATIONSHIPS

The College will be viewed as a valued resource for the dissemination of authoritative

knowledge of brain disorders and their treatment and will advance the scientific goals

of the College through collaborative relationships with patient advocacy organizations,

government, academia and industry.


Decrease the ACNP’s susceptibility to perceptions from members, the media, and

others that may undermine ACNP’s effectiveness in communicating scientific

information.

Increase the use of our website and related online tools by members, media and

the public at large.

Increase the ACNP’s ability to effectively and rapidly respond to events that are

important to the mission of the College and our members.

Develop and maintain a relationship with the lay leadership and scientific

leadership of disease specific advocacy groups.

Possible Strategies:

4.1 Work to foster effective alliances among academia, industry, government (e.g.

NIH, FDA), and patient advocacy groups to facilitate research into the causes of

neuropsychiatric disorders and to develop improved treatments, cures, and

preventive measures.

4.2 Maintain appropriate relationships between the College and industry by

continually monitoring compliance with our policies and the effectiveness of our

conflict of interest firewalls.

4.2 In all aspects of official ACNP business, continue to require meaningful

disclosure of relationships that might appear to represent a conflict of interest.

4.3 Increase the amount of scientific information for the public, media, consumers,

families, scientists and practitioners that is freely available on the ACNP Website

and related online tools.

4.4 Use the ACNP Journal when appropriate for publishing important position

statements.

4.5 Foster meaningful and continuous dialogue with NIH Institute Directors and the

membership.

4.6 ACNP will maintain relationships with other organizations whose mission and

purpose is closely aligned with that of ACNP (e.g. NABR) and will support those

that make significant contributions toward the achievement of goals that are

important to the ACNP mission and purpose.

acnp summer council meeting agenda 8:30 a.m. 3:30 p.m. est...

Documents